
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Oncol</journal-id><journal-title-group><journal-title>Translational Oncology</journal-title></journal-title-group><issn pub-type="epub">1936-5233</issn><publisher><publisher-name>Neoplasia Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33069104</article-id><article-id pub-id-type="pmc">7562988</article-id><article-id pub-id-type="pii">S1936-5233(20)30397-1</article-id><article-id pub-id-type="doi">10.1016/j.tranon.2020.100905</article-id><article-id pub-id-type="publisher-id">100905</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review article</subject></subj-group></article-categories><title-group><article-title>Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>McCann</surname><given-names>Emma</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>O'Sullivan</surname><given-names>Jacintha</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Marcone</surname><given-names>Simone</given-names></name><email>marcones@ucd.ie</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0001"><label>a</label>Department of Surgery, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland</aff><aff id="aff0002"><label>b</label>M.Sc. in Translational Oncology, Trinity College Dublin, Dublin, Ireland</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author. <email>marcones@ucd.ie</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>14</day><month>10</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2020</year></pub-date><volume>14</volume><issue>1</issue><elocation-id>100905</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier Inc.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0001"><p>Radiotherapy is a regimen that uses ionising radiation (IR) to treat cancer. Despite the availability of several therapeutic options, cancer remains difficult to treat and only a minor percentage of patients receiving radiotherapy show a complete response to the treatment due to development of resistance to IR (radioresistance). Therefore, radioresistance is a major clinical problem and is defined as an adaptive response of the tumour to radiation-induced damage by altering several cellular processes which sustain tumour growth including DNA damage repair, cell cycle arrest, alterations of oncogenes and tumour suppressor genes, autophagy, tumour metabolism and altered reactive oxygen species. Cellular organelles, in particular mitochondria, are key players in mediating the radiation response in tumour, as they regulate many of the cellular processes involved in radioresistance. In this article has been reviewed the recent findings describing the cellular and molecular mechanism by which cancer rewires the function of the mitochondria and cellular metabolism to enhance radioresistance, and the role that drugs targeting cellular bioenergetics have in enhancing radiation response in cancer patients.</p></abstract><abstract abstract-type="graphical" id="abs0002"><title>Graphical abstract</title><p><fig id="fig0002" position="anchor"><alt-text id="alttx001">Image, graphical abstract</alt-text><graphic xlink:href="fx1"/></fig></p></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Mitochondrial dysfunction</kwd><kwd>Cancer metabolism</kwd><kwd>Radiotherapy</kwd><kwd>Radioresistance</kwd><kwd>Cancer treatment</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0001">Cancer is a multifactorial disease and the choice of treatment options is dependent on many factors. Therapeutic options include surgery, chemotherapy, immunotherapy, targeted and endocrine therapies, and radiation therapy <xref rid="bib0001" ref-type="bibr">[1</xref>,<xref rid="bib0002" ref-type="bibr">2]</xref>. Despite the availability of these options cancer remains difficult to treat, particularly in advanced stages, with treatment resistance contributing to cancer progression and mortality <xref rid="bib0003" ref-type="bibr">[3]</xref>. Radiation therapy represents a method used to treat locally advanced cancer and roughly half of cancer patients are treated with radiotherapy in conjunction with surgery and/or chemotherapy, as primary therapy <xref rid="bib0004" ref-type="bibr">[4]</xref>. Radiotherapy uses high doses of ionizing radiation (IR) to evoke cell death primarily by causing cellular DNA damage <xref rid="bib0005" ref-type="bibr">[5]</xref>. Resistance to radiation also known as radioresistance is a major clinical problem in various cancer types including glioblastoma <xref rid="bib0006" ref-type="bibr">[6]</xref>, breast <xref rid="bib0007" ref-type="bibr">[7]</xref> as well as oesophageal adenocarcinoma <xref rid="bib0008" ref-type="bibr">[8]</xref>. Radioresistance can be defined as a process wherein the adaptation of tumour cells to radiotherapy-induced damage leads to developing resistance to IR. Radioresistance is a complex process involving alteration of several cellular mechanisms including DNA damage repair mechanisms, cell cycle arrest, oncogenes and tumour suppressor genes, tumour microenvironment changes, autophagy, cancer stem cells generation, tumour metabolism and altered regulation of reactive oxygen species <xref rid="bib0002" ref-type="bibr">[2</xref>,<xref rid="bib0009" ref-type="bibr">9]</xref>. In addition, cellular organelles are important targets of IR and they play a significant role in mediating radiation cytotoxic effects. It has been shown that radiation can damage the endoplasmic reticulum, induce changes in the ribosome, damage the lysosome, affect the biological properties and the signal transduction of the plasma membrane, and affect mitochondrial function <xref rid="bib0005" ref-type="bibr">[5]</xref>. DNA damage induced by IR can result in a massive alteration in mitochondria function as the mitochondrial DNA is genetically denser compared to the nuclear genome <xref rid="bib0010" ref-type="bibr">[10]</xref>. Mitochondria are doubled membraned organelles that play vital roles in physiological cellular processes such as energy production, macromolecule biosynthesis, gene expression, apoptosis, calcium homoeostasis and regulation of ROS production <xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>. Many of these mitochondrial processes are altered in cancer <xref rid="bib0014" ref-type="bibr">[14]</xref> and increasing evidence suggests that altered mitochondria morphology and metabolism are associated with radioresistance <xref rid="bib0015" ref-type="bibr">[15]</xref>. In particular, energy metabolism reprogramming is an emerging hallmark of cancer <xref rid="bib0016" ref-type="bibr">[16]</xref> which plays a critical role in radioresponse <xref rid="bib0002" ref-type="bibr">[2]</xref>. Warburg effect is the best-known example of energy metabolism reprogramming in cancer, where cancer cells preferentially use the less efficient glycolytic pathway even in the presence of oxygen to generate energy and to produce important molecules sustaining cancer progression <xref rid="bib0017" ref-type="bibr">[17]</xref>. In recent years increasing evidence demonstrates that rewiring of mitochondrial function and metabolism plays an important role in tumour progression and response to treatment by modulating the mitochondrial energy production processes <xref rid="bib0015" ref-type="bibr">[15]</xref>. In this article have been reviewed the recent findings, summarised in <xref rid="fig0001" ref-type="fig">Fig.&#x000a0;1</xref> and in <xref rid="tbl0001" ref-type="table">Table&#x000a0;1</xref>, describing the cellular and molecular mechanisms by which cancer rewires the function of the mitochondria and metabolism to enhance radioresistance, and the role that drugs targeting bioenergetic have in enhancing radiation response.<fig id="fig0001"><label>Fig. 1</label><caption><p>Cellular mechanisms contributing to radioresistance through rewiring of mitochondrial function and metabolism in cancer.</p></caption><alt-text id="alt0001">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Summary of the findings describing the mechanisms of radioresistance regulated by mitochondrial dysfunction and altered metabolism in cancer.</p></caption><alt-text id="alt0002">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Altered cellular process</th><th valign="top">Authors</th><th valign="top">Cancer type</th><th valign="top">Mechanism of radioresistance</th><th valign="top">Ref</th></tr></thead><tbody><tr><td rowspan="9" align="left" valign="top"><bold>Redox balance</bold></td><td valign="top">Lynam-Lennon, N. et&#x000a0;al.</td><td valign="top">Oesophageal adenocarcinoma</td><td valign="top">Higher basal level of ROS</td><td valign="top"><xref rid="bib0015" ref-type="bibr">[15]</xref></td></tr><tr><td valign="top">Wei, Y. et&#x000a0;al.</td><td valign="top">Non-small cell lung carcinoma</td><td valign="top">Lower radiation-induced ROS level</td><td valign="top"><xref rid="bib0019" ref-type="bibr">[19]</xref></td></tr><tr><td valign="top">Lynam-Lennon, N. et&#x000a0;al.</td><td valign="top">Oesophageal adenocarcinoma</td><td valign="top">Maintenance of glutathione levels stable post irradiation</td><td valign="top"><xref rid="bib0021" ref-type="bibr">[21]</xref></td></tr><tr><td valign="top">Hanot, M. et&#x000a0;al.</td><td valign="top">Tongue squamous cell carcinoma</td><td valign="top">Altered glutathione levels</td><td valign="top"><xref rid="bib0022" ref-type="bibr">[22]</xref></td></tr><tr><td valign="top">Chen, X. et&#x000a0;al.</td><td valign="top">Oesophageal squamous cell carcinoma</td><td valign="top">Increased IDH2 expression</td><td valign="top"><xref rid="bib0024" ref-type="bibr">[24]</xref></td></tr><tr><td valign="top">Sun, J. et&#x000a0;al.</td><td valign="top">CHO cells</td><td rowspan="4" align="left" valign="top">MnSOD overexpression</td><td valign="top"><xref rid="bib0020" ref-type="bibr">[20]</xref></td></tr><tr><td valign="top">Hirose, K. et&#x000a0;al.</td><td valign="top">Melanoma</td><td valign="top"><xref rid="bib0025" ref-type="bibr">[25]</xref></td></tr><tr><td valign="top">Kalen, A.L. et&#x000a0;al.</td><td valign="top">Head-and-neck cancers</td><td valign="top"><xref rid="bib0026" ref-type="bibr">[26]</xref></td></tr><tr><td valign="top">Fisher, C.J. et&#x000a0;al.</td><td valign="top">Pancreatic</td><td valign="top"><xref rid="bib0027" ref-type="bibr">[27]</xref></td></tr><tr><td rowspan="7" align="left" valign="top"><bold>DNA repair</bold></td><td valign="top">Lynam-Lennon, N. et&#x000a0;al.</td><td valign="top">Oesophageal adenocarcinoma</td><td valign="top">Increased repair of radiation-induced DNA damage</td><td valign="top"><xref rid="bib0021" ref-type="bibr">[21]</xref></td></tr><tr><td valign="top">Hyun, J. W. et&#x000a0;al.</td><td valign="top">Leukaemia</td><td valign="top">Low OGG1 activity</td><td valign="top"><xref rid="bib0042" ref-type="bibr">[42]</xref></td></tr><tr><td valign="top">Ramdzan, Z.M. et&#x000a0;al.</td><td valign="top">Breast, Lung, Glioblastoma, Colorectal</td><td valign="top">CUX1 overexpression</td><td valign="top"><xref rid="bib0046" ref-type="bibr">[46]</xref></td></tr><tr><td valign="top">Wang, Y. et&#x000a0;al.</td><td valign="top">Non-small cell lung carcinoma</td><td valign="top">Downregulation of SSBP1</td><td valign="top"><xref rid="bib0054" ref-type="bibr">[54]</xref></td></tr><tr><td valign="top">Roy, K. et&#x000a0;al.</td><td valign="top">Glioma</td><td valign="top">Methylation of the ATM promoter</td><td valign="top"><xref rid="bib0056" ref-type="bibr">[56]</xref></td></tr><tr><td valign="top">Squatrito, M. et&#x000a0;al.</td><td valign="top">Glioblastoma</td><td valign="top">Loss of components in the ATM/Chk2/p53 pathway</td><td valign="top"><xref rid="bib0057" ref-type="bibr">[57]</xref></td></tr><tr><td valign="top">You, W.C. et&#x000a0;al.</td><td valign="top">Glioblastoma</td><td valign="top">ATAD3A-mediated attenuation of DSB repairs</td><td valign="top"><xref rid="bib0058" ref-type="bibr">[58]</xref></td></tr><tr><td rowspan="3" align="left" valign="top"><bold>Apoptosis</bold></td><td valign="top">He, Q. <italic>et al</italic></td><td valign="top">Oesophageal squamous cell carcinoma</td><td valign="top">High LKB1 expression</td><td valign="top"><xref rid="bib0066" ref-type="bibr">[66]</xref></td></tr><tr><td valign="top">Wang, Z. et&#x000a0;al.</td><td valign="top">Mouse embryonic fibroblasts</td><td valign="top">MKP1 inhibition of JNK-mediated apoptosis</td><td valign="top"><xref rid="bib0068" ref-type="bibr">[68]</xref></td></tr><tr><td valign="top">Candas, D. et&#x000a0;al.</td><td valign="top">HER2-positive breast cancer</td><td valign="top">MKP1 overexpression</td><td valign="top"><xref rid="bib0148" ref-type="bibr">[148]</xref></td></tr><tr><td rowspan="4" align="left" valign="top"><bold>Cell cycle checkpoints</bold></td><td valign="top">Wei, Y. et&#x000a0;al.</td><td valign="top">Non-small cell lung carcinoma</td><td valign="top">Prolonged G2 arrest</td><td valign="top"><xref rid="bib0019" ref-type="bibr">[19]</xref></td></tr><tr><td valign="top">Cloos, <italic>C. R.</italic> et&#x000a0;al.</td><td valign="top">Pancreatic</td><td valign="top">Supressed G2 activation increased cyclin B1 and CDK1</td><td valign="top"><xref rid="bib0077" ref-type="bibr">[77]</xref></td></tr><tr><td valign="top">Muschel, <italic>R. J.,</italic> et&#x000a0;al.</td><td valign="top">Cervical cancer</td><td valign="top">Altered Cyclin B expression</td><td valign="top"><xref rid="bib0078" ref-type="bibr">[78]</xref></td></tr><tr><td valign="top">Liu, R. et&#x000a0;al.</td><td valign="top">Colon, Glioblastoma, Breast</td><td valign="top">Increased SIRT3 activity</td><td valign="top"><xref rid="bib0080" ref-type="bibr">[80]</xref></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Mitochondria-to-nucleus retrograde signaling</bold></td><td valign="top">Wei, Y. et&#x000a0;al.</td><td valign="top">Non-small cell lung carcinoma</td><td valign="top">NF-&#x003ba;B/ PI3K/AKT2/mTOR activation</td><td valign="top"><xref rid="bib0019" ref-type="bibr">[19]</xref></td></tr><tr><td valign="top">Cloos, C. R. et&#x000a0;al.</td><td valign="top">Pancreatic cancer</td><td valign="top">Mitochondrial DNA depletion</td><td valign="top"><xref rid="bib0077" ref-type="bibr">[77]</xref></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Mitochondrial membrane potential</bold></td><td valign="top">Dong, Q. et&#x000a0;al.</td><td valign="top">Oesophageal carcinoma</td><td valign="top">Modulation of BMI-1 expression</td><td valign="top"><xref rid="bib0084" ref-type="bibr">[84]</xref></td></tr><tr><td valign="top">Li, Y.L. et&#x000a0;al.</td><td valign="top">Head and neck cancers</td><td valign="top">Increased GDF15 expression</td><td valign="top"><xref rid="bib0085" ref-type="bibr">[85]</xref></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Mitochondrial ion channels</bold></td><td valign="top">Huang, L. et&#x000a0;al.</td><td valign="top">Glioma</td><td valign="top">Overexpression of mtK<sub>ATP</sub> channel</td><td valign="top"><xref rid="bib0086" ref-type="bibr">[86]</xref></td></tr><tr><td valign="top">Arif, T. et&#x000a0;al.</td><td valign="top">Breast, lung Glioblastoma</td><td valign="top">VDAC1 overexpression</td><td valign="top"><xref rid="bib0014" ref-type="bibr">[14]</xref></td></tr><tr><td rowspan="6" align="left" valign="top"><bold>Glycolysis</bold></td><td valign="top">Pitroda, S.P. et&#x000a0;al.</td><td valign="top">Tongue squamous cell carcinoma</td><td valign="top">STAT1 regulation of energy metabolism</td><td valign="top"><xref rid="bib0091" ref-type="bibr">[91]</xref></td></tr><tr><td valign="top">De Schutter, H. et&#x000a0;al.</td><td valign="top">Head and neck cancers</td><td rowspan="2" align="left" valign="top">GLUT1 overexpression</td><td valign="top"><xref rid="bib0095" ref-type="bibr">[95]</xref></td></tr><tr><td valign="top">Kunkel, M. et&#x000a0;al.</td><td valign="top">Oral cavity squamous carcinoma</td><td valign="top"><xref rid="bib0096" ref-type="bibr">[96]</xref></td></tr><tr><td valign="top">Blatt, S. et&#x000a0;al.</td><td rowspan="2" align="left" valign="top">Head and neck cancers</td><td rowspan="2" align="left" valign="top">High levels of lactate</td><td valign="top"><xref rid="bib0097" ref-type="bibr">[97]</xref></td></tr><tr><td valign="top">Sandulache, V.C. et&#x000a0;al.</td><td valign="top"><xref rid="bib0098" ref-type="bibr">[98]</xref></td></tr><tr><td valign="top">Hao, J. et&#x000a0;al.</td><td valign="top">Prostate</td><td valign="top">Increased LDHA</td><td valign="top"><xref rid="bib0099" ref-type="bibr">[99]</xref></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Glutamine metabolism</bold></td><td valign="top">Li, D. et&#x000a0;al.</td><td valign="top">Pancreatic</td><td valign="top">Non-canonical glutamine metabolism pathway</td><td valign="top"><xref rid="bib0107" ref-type="bibr">[107]</xref></td></tr><tr><td valign="top">Xiang, L. et&#x000a0;al.</td><td valign="top">Cervical</td><td valign="top">Increased GLS2 expression</td><td valign="top"><xref rid="bib0105" ref-type="bibr">[105]</xref></td></tr><tr><td rowspan="4" align="left" valign="top"><bold>Oxidative phosphorylation</bold></td><td valign="top">Lynam-Lennon et&#x000a0;al.</td><td valign="top">Oesophageal adenocarcinoma</td><td valign="top">Increased ATP5B expression</td><td valign="top"><xref rid="bib0015" ref-type="bibr">[15]</xref></td></tr><tr><td valign="top">Le Bleu, V.S. et&#x000a0;al.</td><td valign="top">Breast</td><td valign="top">Increased PGC1&#x003b1;</td><td valign="top"><xref rid="bib0110" ref-type="bibr">[110]</xref></td></tr><tr><td valign="top">Viale, A. <italic>et al</italic></td><td valign="top">Pancreatic</td><td valign="top">Increased expression of OXPHOS genes</td><td valign="top"><xref rid="bib0112" ref-type="bibr">[112]</xref></td></tr><tr><td valign="top">Grasso, D. et&#x000a0;al.</td><td valign="top">Head and neck cancer</td><td valign="top">Increased OXPHOS metabolism</td><td valign="top"><xref rid="bib0113" ref-type="bibr">[113]</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0002"><title>Role of mitochondria in radioresistance</title><p id="para0002">The latest findings describing the mitochondrial processes altered in cancer which are involved in radioresistance have been reviewed in this section.</p><sec id="sec0003"><title>Mitochondria and redox balance in cancer</title><sec id="sec0004"><title>Ros and radioresistance</title><p id="para0003">Mitochondria play a key role in the regulation of cellular redox balance thought modulation of Reactive Oxygen Species (ROS) generation <xref rid="bib0011" ref-type="bibr">[11]</xref>. Increased levels of ROS have been found in most cancers to support tumour development and growth; on the other side, tumour cells also have increased expression of antioxidants, which are responsible for ROS detoxification, suggesting that a delicate balance between ROS and antioxidants is required to sustain cancer cell growth <xref rid="bib0018" ref-type="bibr">[18]</xref>. However, IR induces abnormal production of ROS which, in turn, trigger DNA damage leading to cancer cell apoptosis. It has been shown that IR can cause mtDNA damage/deletion altering mitochondrial functions and leading to persistent production of cytotoxic superoxide <xref rid="bib0010" ref-type="bibr">[10]</xref>. Lynam-Lennon et&#x000a0;al. have shown that radioresistant oesophageal adenocarcinoma cell line had significant higher basal levels of random mutations in the mitochondrial genome compared to its isogenic radiosentitive cell line, due to radiation bystander effects <xref rid="bib0015" ref-type="bibr">[15]</xref>. Mitochondria can adapt to DNA deletion damage by increasing their DNA copy number and quantity which can influence radiotherapy response <xref rid="bib0010" ref-type="bibr">[10</xref>,<xref rid="bib0015" ref-type="bibr">15]</xref>. In addition, ROS basal level was significantly higher in the radioresistant oesophageal adenocarcinoma cells, and an increase in ROS levels and in mitochondrial mass after IR was only detected in the radiosensitive cell. These findings suggested that the chronic oxidative stress present in the radioresistant cells inferred resistance to IR-induced oxidative stress <xref rid="bib0015" ref-type="bibr">[15]</xref>. Interestingly, it has been reported that mtDNA depletion induced significantly lower levels of ROS production after IR and a radioresistant phenotype compared to cells with functional mitochondria <xref rid="bib0019" ref-type="bibr">[19]</xref>.</p></sec><sec id="sec0005"><title>Antioxidants and radioresistance</title><p id="para0004">Glutathione peroxidase and superoxide dismutase are ROS scavengers that function by catalysing ROS detoxification reactions to protect the cells against oxidative stress <xref rid="bib0020" ref-type="bibr">[20]</xref>. Increased levels of antioxidant enzymes have been linked to radioresistance in various cancer types. It has been showed that radioresistant oesophageal adenocarcinoma cells could maintain their basal level of glutathione post-irradiation stable, suggesting that this mechanism can play a role in their radioresistant phenotype <xref rid="bib0021" ref-type="bibr">[21]</xref>. <italic>In vitro</italic> models of head and neck cancer and Chinese hamster ovary cells showed that increased expression of antioxidants involved in the glutathione system, such as glutathione and glutathione peroxidase, was linked to radioresistance and increased survival <xref rid="bib0020" ref-type="bibr">[20</xref>,<xref rid="bib0022" ref-type="bibr">22]</xref>. However, in mouse squamous cell carcinoma derived cell line, glutathione and its associated enzymes played no part in their intrinsic radioresistance <xref rid="bib0023" ref-type="bibr">[23]</xref>.</p><p id="para0005">Isocitrate dehydrogenase 2 (IDH2) is a mitochondrial enzyme that catalyse the oxidative decarboxylation of isocitrate into alpha-ketoglutarate in the citric acid cycle. It has been shown that IDH2 played a key role in the radioresistance of oesophageal squamous cell carcinoma by increased the radiation-induced ROS level, oxidative damage, and cell apoptosis in IDH2 knockdown cells <xref rid="bib0024" ref-type="bibr">[24]</xref>.</p><p id="para0006">Manganese superoxide dismutase (MnSOD) is a mitochondrial antioxidant associated to radioresistance <xref rid="bib0025" ref-type="bibr">[25]</xref>. Several <italic>in vitro</italic> studies have shown that MnSOD overexpression is linked with increased cell survival and resistance to IR in various cancer types, suggesting that MnSOD might represent a potential therapeutic target <xref rid="bib0026" ref-type="bibr">[26</xref>,<xref rid="bib0027" ref-type="bibr">27]</xref>. MnSOD also plays a role in mitochondrial stability as its overexpression protected against the initial decrease in mitochondrial transmembrane potential (&#x00394;&#x003a8;) after IR, an important step in the initiation of IR-induced apoptosis pathway <xref rid="bib0028" ref-type="bibr">[28]</xref>.</p><p id="para0007">Catalase is an antioxidant enzyme responsible for conversion of H<sub>2</sub>O<sub>2,</sub> generated during cellular stress conditions, to water and oxygen. A study focused to determine whether increased catalase was radioprotective showed that mitochondrially targeted overexpression of the catalase transgene was having radioprotective effect <italic>in vitro</italic> and <italic>in vivo,</italic> suggesting a potential strategy for radioprotection of normal tissues during radiation therapy <xref rid="bib0028" ref-type="bibr">[28]</xref>. In addition, Epperly et&#x000a0;al. <xref rid="bib0029" ref-type="bibr">[29</xref>,<xref rid="bib0030" ref-type="bibr">30]</xref> showed that overexpression of both mitochondrial MnSOD and mitochondrial catalase transgenes was superior to one alone for radioprotection of specific organs including <italic>in vivo</italic> models of oral cavity <xref rid="bib0030" ref-type="bibr">[30]</xref>, bladder <xref rid="bib0031" ref-type="bibr">[31]</xref>, lung <xref rid="bib0032" ref-type="bibr">[32]</xref> and oesophagus <xref rid="bib0033" ref-type="bibr">[33]</xref>.</p></sec></sec><sec id="sec0006"><title>Mitochondrial dysfunction, DNA repair and radioresistance</title><p id="para0008">DNA repair mechanisms play a fundamental role in the control of response to IR, and enhanced DNA repair was associated with radioresistance in cancer <xref rid="bib0021" ref-type="bibr">[21]</xref>. A number of studies have shown that the mitochondrial DNA (mtDNA) is more sensitive to IR than nuclear DNA <xref rid="bib0034" ref-type="bibr">[34]</xref>, <xref rid="bib0035" ref-type="bibr">[35]</xref>, <xref rid="bib0036" ref-type="bibr">[36]</xref>, possibly due to its close proximity to ROS and its denser genome <xref rid="bib0036" ref-type="bibr">[36</xref>,<xref rid="bib0037" ref-type="bibr">37]</xref>. Thymine glycol and 8-oxoGuanine are considered to be the major products of mtDNA oxidation damage induced by IR, contributing broadly to oxidative damage-induced mutations. DNA base alterations are repaired by base excision repair (BER) enzymes as demonstrated in a number of mammalian models <xref rid="bib0037" ref-type="bibr">[37]</xref>, <xref rid="bib0038" ref-type="bibr">[38]</xref>, <xref rid="bib0039" ref-type="bibr">[39]</xref>. Enzymes important in BER repair such as DNA glycosylases, abasic-endonucleases (APE), DNA polymerase, and DNA ligase have been found to be either localised to the mitochondria or actively transported to the mitochondria <xref rid="bib0040" ref-type="bibr">[40]</xref>. Oxoguanine glycosylase (OGG1) is a major DNA glycosylase enzyme involved in repair of 8&#x02011;hydroxy&#x02011;2&#x02032;-deoxyguanosine mutation, and it has been shown to have an important role in mtDNA damage repair, a key mechanism regulating radiation response <xref rid="bib0037" ref-type="bibr">[37</xref>,<xref rid="bib0041" ref-type="bibr">41]</xref>. Hyun et&#x000a0;al. showed that a loss of OGG1 was associated with enhanced radiosensitivity in acute lymphocytic leukaemia, thereby highlighting an important role of OGG1 in radioprotection <xref rid="bib0042" ref-type="bibr">[42]</xref>. In addition, the enzymatic activity of OGG1 is directly stimulated by both CUX1 <xref rid="bib0043" ref-type="bibr">[43</xref>,<xref rid="bib0044" ref-type="bibr">44]</xref> and CUX2 <xref rid="bib0045" ref-type="bibr">[45]</xref>, haploinsufficient tumour suppressor genes which play an important role in radioresistance <xref rid="bib0046" ref-type="bibr">[46]</xref>. Interestingly, CUX1 gene copy number is increased in over 70% of human cancers, and its expression inversely correlates with patient survival <xref rid="bib0047" ref-type="bibr">[47</xref>,<xref rid="bib0048" ref-type="bibr">48]</xref>. CUX1 knockdown was lethal to cancer cells following ionizing radiation <xref rid="bib0046" ref-type="bibr">[46]</xref>. Several drugs that inhibit BER enzymes, such as PARP1 and APE1, are tested in the clinic with different treatment modalities (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" id="interref0001">https://clinicaltrials.gov/</ext-link>) to treat cancer. However, BER enzymes exert essential functions in human tissues since over 30,000 base alterations/day are produced in healthy cells <xref rid="bib0049" ref-type="bibr">[49]</xref>, thus its inhibition is associated with side effects. In contrast, CUX1 only functions as an auxiliary factor that accelerates repair of oxidative damage <xref rid="bib0044" ref-type="bibr">[44</xref>,<xref rid="bib0050" ref-type="bibr">50]</xref>, therefore it is not essential in normal human cells <xref rid="bib0051" ref-type="bibr">[51]</xref> suggesting that CUX1 might represent an ideal therapeutic target for cancer treatment.</p><p id="para0009">Mitochondrial Single Stranded DNA Binding Protein 1 (SSBP1) is part of the single-stranded DNA binding protein family which are guardians of genome stability controlling DNA damage response in the cell <xref rid="bib0052" ref-type="bibr">[52]</xref>. In an <italic>in vitro</italic> model of osteoblastoma it was shown that SSBP1 expression was linked to cancer progression, suggesting its use as a prognostic biomarker <xref rid="bib0053" ref-type="bibr">[53]</xref>. Downregulation of SSBP1 has been associated to increased radiosensitivity in lung cancer by decreasing the mtDNA copy number and mitochondrial morphology and function <xref rid="bib0054" ref-type="bibr">[54]</xref>.</p><p id="para0010">IR produces a wide variety of DNA damages. Double-strand breaks (DSBs) are considered to be the major effectors for IR-induced cell death <xref rid="bib0055" ref-type="bibr">[55]</xref>. Once DSBs occur, numerous sensor proteins,including ataxia-telangiectasia, Rad3-related, DNA-dependant protein kinase and ataxia-telangiectasia mutated, are recruited to the site of the damage (ATM) <xref rid="bib0004" ref-type="bibr">[4]</xref>. It has been shown that ATM plays an important role in glioblastoma response to IR, as cells lacking the ATM protein were highly sensitive to ionizing radiation and <xref rid="bib0056" ref-type="bibr">[56]</xref>. Another study showed that loss of components in the ATM/Chk2/p53 pathway was associated with radioresistance in a glioma mouse model, and it was demonstrated that Chk2 is required for glioma response to IR <xref rid="bib0057" ref-type="bibr">[57]</xref>. In addition, <italic>in vitro</italic> models of glioblastoma showed that mitochondrial enzyme ATAD3A plays a role in ATM function as silencing of ATAD3A was associated with attenuation of DSB repairs and enhanced radiosensitivity <xref rid="bib0058" ref-type="bibr">[58</xref>,<xref rid="bib0059" ref-type="bibr">59]</xref>.</p></sec><sec id="sec0007"><title>Mitochondria, apoptosis and radioresistance</title><p id="para0011">One of the hallmarks of cancer is the ability of cancer cells to avoid apoptosis <xref rid="bib0060" ref-type="bibr">[60]</xref>. Evasion of apoptosis in cancer is associated with treatment resistance to IR. IR primarily triggers the mitochondrial dependent pathway of apoptosis and therefore mitochondria dysfunction in cancer plays a crucial role in regulating treatment resistance and evasion of apoptosis <xref rid="bib0061" ref-type="bibr">[61]</xref>..</p><p id="para0012">Human tumour suppressor LKB1 is a primary upstream kinase of adenosine monophosphate-activated protein kinase (AMPK) pathway, a necessary element in cell metabolism that is required for maintaining energy homoeostasis, metabolism, polarity, growth and autophagy <xref rid="bib0062" ref-type="bibr">[62]</xref>, <xref rid="bib0063" ref-type="bibr">[63]</xref>, <xref rid="bib0064" ref-type="bibr">[64]</xref>. Saigusa et&#x000a0;al. showed that in locally advanced rectal cancer treated with neoadjuvant chemo-radiation therapy the expression of LKB1 was higher in patients with tumour recurrence and poor pathological response, demonstrating that LKB1 may play a role in treatment resistance <xref rid="bib0065" ref-type="bibr">[65]</xref>. In addition, it was demonstrated that overexpression of LKB1 induced radioresistance by inhibiting apoptosis and by activating autophagy, suggesting that LKB1 might be a novel therapeutic target to maximise radiation response in oesophageal cancer <xref rid="bib0066" ref-type="bibr">[66]</xref>.</p><p id="para0013">Mitogen-activated protein kinase (MAPK) phosphatase (MKP)&#x02212;1 is the major member of MKPs that dephosphorylates and inactivates MAPK, a major signaling transduction molecules in apoptosis <xref rid="bib0067" ref-type="bibr">[67]</xref>. In a study was demonstrated that IR-induced MKP-1 played an anti-apoptotic function <italic>via</italic> inhibition of JNK-mediated proapoptotic pathway, and siRNA-mediated inhibition of MKP-1 significantly enhanced apoptotic response in irradiated cells <xref rid="bib0068" ref-type="bibr">[68]</xref>.</p></sec><sec id="sec0008"><title>Mitochondria dysfunction and the cell cycle checkpoints in cancer cell radioresistance</title><p id="para0014">Cell cycle checkpoints are often violated in cancer due to increased expression of growth factors and evading growth suppressors which lead to dysregulation of cell progression control mechanisms <xref rid="bib0016" ref-type="bibr">[16]</xref>. After exposure to IR, eukaryotic cells undergo a division delay which is reflected by increased time spent in the G2 portion of the cell cycle. The cell cycle checkpoints are regulated by cyclin-cyclin dependent kinases (CDK) complexes, and theG2/M checkpoint which controls progression to mitosis is primarily controlled by Cyclin B1-CDK1 complex activity <xref rid="bib0069" ref-type="bibr">[69]</xref>. Cyclin B1 has been found overexpressed in various cancers including oesophageal squamous cell carcinoma <xref rid="bib0070" ref-type="bibr">[70]</xref>, non-small cell lung cancer <xref rid="bib0071" ref-type="bibr">[71]</xref>, oral carcinoma <xref rid="bib0072" ref-type="bibr">[72]</xref>, prostate adenocarcinoma <xref rid="bib0073" ref-type="bibr">[73]</xref>, breast cancer <xref rid="bib0074" ref-type="bibr">[74]</xref>, astrocytomas <xref rid="bib0075" ref-type="bibr">[75]</xref> and <italic>Helicobacter pylori</italic>-associated gastric MALT and MALT lymphoma <xref rid="bib0076" ref-type="bibr">[76]</xref>. It was shown that IR-induced G2 activation was suppressed by mtDNA depletion in human pancreas cancer cell and was accompanied by increased levels of Cyclin B1 and CDK1. The pancreatic cells with mtDNA depletion were more resistant to IR compared to cells with functional mitochondria <xref rid="bib0077" ref-type="bibr">[77]</xref>. Similarly, mtDNA depletion in lung cancer cells showed prolonged G2 arrest accompanied by a more radioresistant phenotype <xref rid="bib0019" ref-type="bibr">[19]</xref>. It has been shown that a cell division delay was induced when HeLa cells were irradiated in G2 phase which coincided with a lower level of cyclin B protein, identifying cyclin B as a key molecule in the cellular response to ionizing radiation <xref rid="bib0078" ref-type="bibr">[78]</xref>.</p><p id="para0015">SIRT3, a member of the sirtuin family of NAD(+)-dependent protein deacetylases in the mitochondria, regulates mitochondrial processes by promoting metabolic homoeostasis through regulation of mitochondrial protein deacetylation <xref rid="bib0079" ref-type="bibr">[79]</xref>. It has been demonstrated that SIRT3 expression was induced in a number of radiation-treated human cancer cells and xenografts, and it was showed that enhanced SIRT3 transcription and posttranslational modifications contributed to adaptive radioresistance in tumour <xref rid="bib0080" ref-type="bibr">[80]</xref>.</p></sec><sec id="sec0009"><title>MtDNA depletion and radioresistance</title><p id="para0016">Mitochondria-to-nucleus retrograde signalling (RTG) allows crosstalk between the mitochondria and nucleus influencing changes in a variety of cancer cellular phenotypes including survival, metastasis, drug resistance, stemness and metabolism <xref rid="bib0081" ref-type="bibr">[81]</xref>. RTG can be influenced by alterations in the copy number and mutations in mtDNA, respiratory chain component defects in the mitochondria, and loss of mitochondrial membrane potential <xref rid="bib0082" ref-type="bibr">[82]</xref>. Wei et&#x000a0;al. showed that mtDNA depletion in lung cancer may induce radioresistance through activation of the RTG signalling pathway of NF-&#x003ba;B/PI3K/AKT2/mTOR <xref rid="bib0019" ref-type="bibr">[19]</xref>. This requires further study to determine if mtDNA alteration could be used as a predictor of response to radiation therapy and whether NF-&#x003ba;B/PI3K/AKT2/mTOR pathway might represents a potential therapeutic target to enhance radiosensitivity.</p></sec><sec id="sec0010"><title>Mitochondrial membrane and radioresistance</title><p id="para0017">The mitochondrial membrane potential (&#x00394;&#x003a8;) generated by proton pumps (Complexes I, III and IV) is an essential component in the process of energy storage during oxidative phosphorylation <xref rid="bib0083" ref-type="bibr">[83]</xref>. A study showed that histone deacetylase inhibitors (HDAC inhibitor), an emerging anti-cancer therapy, reverse the acquired radioresistance in an <italic>in vitro</italic> oesophageal cancer by modulating polycomb complex protein BMI-1 expression leading to enhanced G2/M arrest, decreased &#x00394;&#x003a8;, increased production of ROS, and enhanced radiation induced apoptosis <xref rid="bib0084" ref-type="bibr">[84]</xref>. Growth differentiation factor 15 (GDF15) is a member of the TGF-&#x003b2; super-family that alters the &#x00394;&#x003a8; inducing ROS suppression. It has been shown than GDF15 promoted cancer stemness, and inhibition of GDF15 sensitised cells to IR <xref rid="bib0085" ref-type="bibr">[85]</xref>.</p><p id="para0018">Mitochondrial ion channels are present on both the inner and outer mitochondrial membrane and play important roles in protein transport, ATP production and Ca<sup>2+</sup> uptake. Mitochondrial ATP-sensitive potassium channel (mtK<sub>ATP</sub>) channel has been shown to have a key role in glioma radioresistance by regulating the ROS activation of EKR pathway. High expression of mtK<sub>ATP</sub> in glioma tissue correlated to shorter survival time and a high malignancy grade, suggesting that use of mtK<sub>ATP</sub> channel blockers in glioma treatment may improve patient outcomes <xref rid="bib0086" ref-type="bibr">[86]</xref>. Voltage-dependent anion channel 1 (VDAC1) is a class of membrane channel acting as a gatekeeper at the outer mitochondrial membrane. VDAC1 is involved in various mitochondrial processes and serves as a link between glycolysis and OXPHOS due to its interaction with hexokinase <xref rid="bib0087" ref-type="bibr">[87]</xref>. It has been shown that depletion of VDAC1 led to inhibition of tumour development and growth of cancer cells in both <italic>in vitro</italic> and <italic>in vivo</italic> models of breast, lung and glioblastoma, as well as and induction of metabolic rewiring reversing the oncogenic properties of cancer cells <xref rid="bib0014" ref-type="bibr">[14]</xref>.</p></sec></sec><sec id="sec0011"><title>Role of metabolism in radioresistance</title><p id="para0019">The alteration of the cellular metabolic pathways in tumour cells, also known as metabolic reprogramming, is considered one of the hallmarks of cancer <xref rid="bib0088" ref-type="bibr">[88]</xref>. Altered activation of oncogenes, inactivation of tumour suppressor genes and changes in cellular signaling pathways are crucial factors regulating metabolic change in tumour <xref rid="bib0089" ref-type="bibr">[89</xref>,<xref rid="bib0090" ref-type="bibr">90]</xref>. Increasing number of evidences suggest that metabolic reprograming in cancer is one of the major factors contributing to radioresistance to IR <xref rid="bib0091" ref-type="bibr">[91]</xref>.Mitochondria play a key role in this process. Mitochondria can rapidly adapt to the increasing energy requirements of the tumour by changing energy production processes in the cells, and radioresistance has been associated with changes in the mitochondrial energy metabolism profile, mitochondrial size, morphology and functions <xref rid="bib0015" ref-type="bibr">[15]</xref>. Carbohydrates are the preferred source of cellular energy in the cells participating in the process of the metabolism of glucose by glycolysis and OXPHOS <xref rid="bib0092" ref-type="bibr">[92]</xref>. Alterations in the glycolytic metabolism in cancer has been shown to contribute to radioresistance development <xref rid="bib0091" ref-type="bibr">[91]</xref>. A class of transporter proteins, GLUT family, is required by the cell for glucose metabolism in the cell <xref rid="bib0093" ref-type="bibr">[93]</xref>. Increasing evidence suggests that high glucose transporter&#x02011;1 (GLUT&#x02011;1) expression is associated with radioresistance in cancer. Abnormal GLUT-1 expression in cancer is regulated by various factors including hypoxia and altered MAPK and PI3K/AKT signalling pathways <xref rid="bib0094" ref-type="bibr">[94]</xref>.Overexpression of GLUT1 was linked to radioresistance in both head and neck squamous cell carcinoma <xref rid="bib0095" ref-type="bibr">[95]</xref> and oral cavity squamous cell carcinoma <xref rid="bib0096" ref-type="bibr">[96]</xref> making it an attractive target for enhancing radiosensitivity. A study showed that GLUT1 inhibitors led to sensitization of radioresistant breast cancer cells to IR, suggesting a potential role of GLUT1 inhibitors as anti-cancer agents <xref rid="bib0094" ref-type="bibr">[94]</xref>. Lactic acid/lactate is a product of glycolysis and high levels of lactate was associated with increased tumour recurrence and poor survival in head and neck cancer patients, suggesting that lactate may have a value as a predictive biomarker of patients survival <xref rid="bib0097" ref-type="bibr">[97]</xref>. Lactate levels have beenassociated with hypoxia-induced radioresistance. A study showed that acute perturbations in tumour lactate levels acted as a surrogate marker of radiation response, suggesting that lactate might be a quantitative biomarker of acute genotoxic stress that could inform clinical decision making <xref rid="bib0098" ref-type="bibr">[98]</xref>. Lactate dehydrogenase (LDHA) is the main metabolic enzyme for lactate generation,a terminal product from glycolysis. It has been demonstrated that knockdown of LDHA could sensitize radioresistant prostate cancer cells to radiotherapy, and proteomic analysis revealed potential protein markers of radioresistance, concluding that targeting LDHA combined with radiotherapy could increase radiosensitivity in radioresistant prostate cancer <xref rid="bib0099" ref-type="bibr">[99]</xref>.</p><p id="para0020">In addition, NOS2, the inducible nitric oxide synthase of iNOS, has been identified as a key molecule upregulated in many aggressive cancer types. Nitric oxide has been demonstrated to act as a modulator of cellular bioenergetic processes and of mitochondrial functions, and therefore has been associated to the alteration of metabolic pathways in cancer <xref rid="bib0100" ref-type="bibr">[100</xref>,<xref rid="bib0101" ref-type="bibr">101]</xref>. Interestingly, iNOS/NOS2-generated nitric oxide has been described as a contributor to radiation resistance in different types of cancer <xref rid="bib0102" ref-type="bibr">[102</xref>,<xref rid="bib0103" ref-type="bibr">103]</xref>.</p><sec id="sec0012"><title>Glutamate metabolism and radioresistance</title><p id="para0021">Glutamate plays key role linking carbohydrate and amino acid metabolism via the tricarboxylic acid (TCA) cycle in the cell <xref rid="bib0104" ref-type="bibr">[104]</xref>. Glutamate is synthesized from glutamine as part of the glutamate&#x02013;glutamine cycle by the enzyme glutaminase. Xiang et&#x000a0;al. showed that a mitochondrial isoform of glutaminase, GLS2, was associated with radioresistance in cervical cancer and its inhibition led to increased radiosensitivity, suggesting that the inhibition of GLS2 may be a potential treatment strategy for radioresistant cervical cancer <xref rid="bib0105" ref-type="bibr">[105]</xref>. A study showed that pancreatic ductal adenocarcinoma tumour growth is facilitated by a KRAS-mediated reprogramming of glutamate metabolism and suggesting that inhibition of glutamine metabolism might potentially synergize with therapies that increase intracellular reactive oxygen species, such as chemotherapy and radiation <xref rid="bib0106" ref-type="bibr">[106]</xref>. It has been shown that pancreatic cancer stem cells relied on the glutamine metabolism pathway and the inhibition of this pathway led to increased radiosensitivity by accumulation of ROS <xref rid="bib0107" ref-type="bibr">[107]</xref>.</p></sec><sec id="sec0013"><title>OXPHOS and radioresistance</title><p id="para0022">Rewiring of energy metabolism in cancer is most commonly associated with a switch from OXPHOS to glycolysis <xref rid="bib0108" ref-type="bibr">[108]</xref>. However increasing evidence demonstrates that cancer cells can use a wide range of energetic profiles, and OXPHOS represents a major source of energy production <xref rid="bib0109" ref-type="bibr">[109]</xref>. It has been previously demonstrated a role for mitochondrial dysfunction and metabolic reprogramming in radioresistance, showing that oesophageal adenocarcinoma radioresistant cells had altered bioenergetics with significantly increased intracellular ATP levels associated to enhanced mitochondrial respiration. Radioresistant cells also demonstrated metabolic plasticity, efficiently switching between the glycolysis and oxidative phosphorylation energy metabolism pathways, accompanied by enhanced clonogenic survival <xref rid="bib0015" ref-type="bibr">[15]</xref>. ATP5B expression, a marker of oxidative phosphorylation, was significantly increased in patients who had a poor pathological response to neoadjuvant CRT, showing a role for specific mitochondrial alterations and metabolic remodelling in the radioresistance of oesophageal adenocarcinoma <xref rid="bib0015" ref-type="bibr">[15]</xref>. A study showed that circulating cancer cells in a mice model of breast cancer had increased expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1&#x003b1;). PGC1&#x003b1; overexpression was associated to a regulation of mitochondrial function by increasing mitochondrial biogenesis and by a preferential use of OXPHOS <xref rid="bib0110" ref-type="bibr">[110]</xref>. It has been also shown that the dependency of pancreatic cancer stem cells on OXPHOS is determined by the balance between PGC1&#x003b1; and Myc <xref rid="bib0111" ref-type="bibr">[111]</xref>. Viale et&#x000a0;al. showed that surviving cells from oncogene ablation in pancreatic cancer were reliant on OXPHOS and responsible for tumour relapse, while inhibition of OXPHOS decreased mitochondrial respiration and the ability of the surviving cells to form spheres affecting their survival <xref rid="bib0112" ref-type="bibr">[112]</xref>. Acquired radioresistance was also associated with a shift from a glycolytic to a more oxidative metabolism and to an increased number of mitochondria with a higher mtDNA content <xref rid="bib0113" ref-type="bibr">[113]</xref>.</p><p id="para0023">Cancer rewires the function of the mitochondria and metabolism to enhance resistance to ionising radiation. Radioresistant phenotype has been associated to alteration of ROS generation, antioxidants level, DNA repair mechanisms, apoptosis, cell cycle checkpoints, mitochondria-to-nucleus retrograde signaling (RTG), membrane potential (&#x00394;&#x003a8;), glycolysis, glutamine metabolism and oxidative phosphorylation (OXPHOS). VDAC1, voltage-dependent anion channel 1; TCA, tricarboxylic acid cycle; ETC, electron transport chain; ATP, adenosine triphosphate; GDF15, growth differentiation factor 15; BMI-1, polycomb complex protein BMI-1; ROS, reactive oxygen species; mtK<sub>ATP</sub>, mitochondrial ATP-sensitive potassium channel; PGC1&#x003b1;, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Cdk1, cyclin-dependent kinase 1; NF-Kb, nuclear Factor kappa-light-chain-enhancer of activated B cells; PI3K, phosphoinositide 3-kinases; AKT2, RAC-beta serine/threonine-protein kinase; mTOR, mammalian target of rapamycin; MKP1, mitogen-activated protein kinase phosphatase 1; LKB1, serine/threonine-protein kinase STK11; JNK, c-Jun N-terminal kinase.</p></sec></sec><sec id="sec0014"><title>Genetic regulation of mitochondria energy metabolism and radioresistance</title><p id="para0024">A set of genes and transcription factors encoded by the nuclear genome regulate mitochondrional biogenesis, functions and trasnscriptional activity. Alteration of these genes are also associated to radioresistance through modulation of mitochondrial function. For example, PGC1&#x003b1; is a co-transcriptional regulation factor important in mitochondrial biogenesis, and upregulation of PGC1&#x003b1; has been linked to chemoresistance and altered energy metabolism in cancer stem cells <xref rid="bib0111" ref-type="bibr">[111</xref>,<xref rid="bib0114" ref-type="bibr">114]</xref>. PGC1&#x003b1; has been linked to radioresistance due to its role in the activation of many others transcription factors including nuclear respiratory factor 1 (NRF1) and 2 (NRF2) which, in turn, are linked to radiation response in cancer <xref rid="bib0115" ref-type="bibr">[115]</xref>. NRF-1 has been linked to the transcriptional control of genes involved in mitochondrial function and biogenesis and it was demonstrated that NRF1 was a direct target of miR-504 <xref rid="bib0116" ref-type="bibr">[116]</xref>. In an <italic>in vitro</italic> model of nasopharyngeal carcinoma, radioresistance was associated with upregulated expression of miR-504, leading to lower levels of NRF1. Serum from nasopharyngeal carcinoma patients showed that miR-504 was up-regulated during different weeks of radiotherapy and correlated with tumour volume, lymph nodes, and metastasis stages, demonstrating that miR-504 regulated radioresistance by down-regulating the expression of NRF1 <xref rid="bib0117" ref-type="bibr">[117]</xref>. NRF2 is a transcriptional regulator of cytoprotective enzyme encoding genes <xref rid="bib0116" ref-type="bibr">[116]</xref> and several studies have shown that aberrant NRF2 regulation is linked to both radioresistance and chemoresistance in various cancers such as lung <xref rid="bib0118" ref-type="bibr">[118]</xref>, prostate <xref rid="bib0119" ref-type="bibr">[119]</xref>, breast <xref rid="bib0120" ref-type="bibr">[120]</xref>, ovarian <xref rid="bib0121" ref-type="bibr">[121]</xref> and oesophageal <xref rid="bib0122" ref-type="bibr">[122]</xref>. These evidences suggest that NRF2 targeting may be a potential treatment strategy for overcoming resistance to treatment. NRF-independent mitochondrial gene expression regulation is orchestrated by other factors such as Sp1 <xref rid="bib0123" ref-type="bibr">[123]</xref>. Sp1 is a transcription factor which regulates mitochondrial functions <xref rid="bib0124" ref-type="bibr">[124</xref>,<xref rid="bib0125" ref-type="bibr">125]</xref>. Deng et&#x000a0;al. showed that high Sp1 expression levels were correlated to cervical cancer progression, and that knockdown of Sp1 significantly enhanced the cellular response to radiation by inducing G2/M arrest, suggesting that Sp1 might represent a potential therapeutic target in cervical cancer <xref rid="bib0126" ref-type="bibr">[126]</xref>. Tumour hypoxia is an important contributor to radioresistance. Hypoxic microenvironment is associated with modulation of expression of genes regulating tumour survival and growth <xref rid="bib0127" ref-type="bibr">[127]</xref>. Hypoxia-inducible factor-1 (HIF-1) is a protein that activates the transcription of many genes involved in angiogenesis, glucose metabolism, cell proliferation and invasion. HIF-1&#x003b1; is overexpressed in human cancer as a result of intratumoral hypoxia as well as genetic alterations <xref rid="bib0128" ref-type="bibr">[128]</xref>. For example, a study showed that radioresistance in glioblastoma is sustained by MEK/ERK regulation of HIF-1&#x003b1;. Signal transduction-based chemotherapy radiosensitised glioblastoma cancer cells by interfering with MEK/ERK pathway preventing HIF-1&#x003b1;-mediated hypoxic cell survival and radiation escape <xref rid="bib0129" ref-type="bibr">[129]</xref>. Interestingly, increasing evidence demonstrates that the switch from oxidative to glycolytic metabolism is an active response to hypoxia mediated by HIF-1&#x003b1;. HIF-1&#x003b1; gene expression alteration in cancer has been associated with altered mitochondrial mass and metabolism, along with increased glucose to pyruvate conversion, and increased cellular influx of glucose, positioning HIF1 as a lead target in radioresistance treatment <xref rid="bib0130" ref-type="bibr">[130]</xref>, <xref rid="bib0131" ref-type="bibr">[131]</xref>, <xref rid="bib0132" ref-type="bibr">[132]</xref>. In addition, a number of studies showed that hypoxia conferred resistance to irradiation through activation of autophagy <xref rid="bib0133" ref-type="bibr">[133]</xref>, <italic>via</italic> c-Jun-mediated Beclin1 expression in lung cancer <xref rid="bib0134" ref-type="bibr">[134]</xref>, and by the HIF-1&#x003b1;/miR-210/Bcl-2 pathway in colon cancer <xref rid="bib0135" ref-type="bibr">[135]</xref>.</p></sec><sec id="sec0015"><title>Targeting mitochondrial energetics for enhanced radiosensitivity</title><p id="para0025">Targeting mitochondrial energetics has emerged as a promising cancer treatment. Studies investigating the role that bioenergetic drugs play in radiation response are increasing <xref rid="bib0136" ref-type="bibr">[136]</xref>. Metformin is a member of the biguanide class of drugs and is widely used as an antidiabetic drug worldwide to treat Type II diabetes <xref rid="bib0114" ref-type="bibr">[114]</xref>. Interestingly, several studies have shown that metformin might have a role as antineoplastic agent, and that metformin is linked to enhanced radiation response in cancer. Storozhuk et&#x000a0;al. demonstrated that metformin inhibited lung cancer cell growth and sensitised them to IR through ATM-AMPK signalling modulation <xref rid="bib0137" ref-type="bibr">[137]</xref>. In another study, metformin <italic>in vitro</italic> treatment of oesophageal cancer cells was shown to act as radiosensitiser leading to an increase in apoptosis, G0/G1 arrest and AMPK activation <xref rid="bib0138" ref-type="bibr">[138]</xref>. In addition, metformin was shown to lead to increased radiosensitivity in pancreatic cancer <italic>in vitro,</italic> and these effects were abrogated by AMPK inhibition <xref rid="bib0139" ref-type="bibr">[139]</xref>. Jin et&#x000a0;al. showed that metformin treatment in colorectal cancer cells was linked to increased expression of AMPK and enhanced radioresistance, and AMPK inhibition led to increased radiosensitivity in these cells <xref rid="bib0140" ref-type="bibr">[140]</xref>. These evidences suggest that AMPK plays an important role in modulating metformin radiosensitiser effects. It has also been reported that metformin sensitised p53-deficient colorectal cancer cells to IR by reducing DNA repair protein levels, and by increasing the proportion of cells in G2/M phase <xref rid="bib0141" ref-type="bibr">[141]</xref>. In addition, it has been shown that resistance to metformin in cancer was linked to increased glycolysis and reduction in mitochondrial metabolism due to mutations in the electron transport chain or to enhanced hypoxia <xref rid="bib0111" ref-type="bibr">[111</xref>,<xref rid="bib0142" ref-type="bibr">142]</xref>. Benej et&#x000a0;al. showed that papaverine, a FDA-approved vasodilator drug, acted as a mitochondria complex I inhibitor, and inhibition of this complex was directly responsible for increased oxygenation and enhanced radiation response in solid tumour. This study suggested that papaverine has the potential to become a clinical radiosensitisers with potentially few side effects as it did not sensitise well-oxygenated normal tissue to IR, thereby increasing the therapeutic index of radiotherapy <xref rid="bib0143" ref-type="bibr">[143]</xref>. In another study, it was demonstrated that inhibition of HIF-1&#x003b1; with 2-methoxyestradiol (2-MeOE2) significantly enhanced radiosensitivity in a radioresistant human melanoma cell model through targeting the glycolysis pathway <xref rid="bib0144" ref-type="bibr">[144]</xref>. Another study showed that dichloroacetate, a pyruvate dehydrogenase kinase (PDK) inhibitor currently being used to treat lactic acidosis, was able to alter glioblastoma cell metabolism by activating mitochondrial toward oxidative phosphorylation and by reversing the radiotherapy-induced glycolytic shift, demonstrating that dichloroacetate was able to sensitize glioblastoma cells to radiotherapy by modulating the metabolic activity of the tumour <xref rid="bib0145" ref-type="bibr">[145]</xref>. Finally, Buckley et&#x000a0;al. showed that pyrazinib, a pyrazine phenol small molecule drug with anti-angiogenic and anti-metabolic activity, was shown to increase radiosensitivity in a model of radioresistant oesophageal adenocarcinoma by modulating mitochondrial bioenergetics, reducing measures of oxidative phosphorylation and glycolysis, therefore supporting further development of pyrazinib as a novel therapeutic radiosensitiser in oesophageal adenocarcinoma <xref rid="bib0146" ref-type="bibr">[146]</xref>.</p></sec><sec id="sec0016"><title>Discussion</title><p id="para0026">Ionising radiation (IR) is one of the most used therapeutic method for the treatment of many cancers. However, due to development of radioresistance by the tumour, IR remains primarily a conservative cancer treatment. Radioresistance is described as a complex process in which the cancerous tissue adapts to the cellular changes induced by IR and develops resistance by modulating multiple genes, factors, and cellular processes. Such processes include alteration of DNA damage repair mechanism, cell cycle, oncogenes, tumour suppressor genes, autophagy, cellular metabolism, and reactive oxygen species. These altered processes are regulated by mitochondria and implicated in cancer treatment response Increasing evidence suggests that mitochondria dysfunction and altered metabolism in cancer plays a key role in radioresistance. In fact, radioresistance in cancer has been associated with changes in the mitochondrial energy metabolism profile, mitochondrial size and number, mitochondrial morphology and function accompanied by increased mitochondrial mutation rate, respiration and intracellular ATP levels <xref rid="bib0015" ref-type="bibr">[15]</xref>. In addition, crosstalk between the mitochondria and nucleus is required for normal cellular function, therefore dysfunction in the mitochondria can lead to alterations in nuclear gene expression and <italic>vice versa</italic>
<xref rid="bib0081" ref-type="bibr">[81]</xref>. A number of studies have shown that alteration of nuclear encoded genes and transcription factors in cancer, which regulate mitochondria processes, can lead to mitochondrial dysfunction and to radioresistance <xref rid="bib0015" ref-type="bibr">[15</xref>,<xref rid="bib0112" ref-type="bibr">112</xref>,<xref rid="bib0147" ref-type="bibr">147]</xref>. In this review we detailed the mechanisms by which cancer rewires the function of the mitochondria and cellular metabolism to enhance resistance to IR. <xref rid="fig0001" ref-type="fig">Fig.&#x000a0;1</xref> shows the various processes and mechanisms described in this article by which the alterations in mitochondrial function and metabolism play a role in radioresistance. Importantly, there are no available radiosensitisers on the market that can be used to increase response in radioresistant cancer, thus, there is increasing interest in identifying the mechanisms regulating radioresistance in order to development targeted novel treatments to enhance radiosensitivity. In this scenario, a number of studies showed that drugs targeting mitochondria bioenergetics such as metformin <xref rid="bib0137" ref-type="bibr">[137]</xref>, <xref rid="bib0138" ref-type="bibr">[138]</xref>, <xref rid="bib0139" ref-type="bibr">[139]</xref>, <xref rid="bib0140" ref-type="bibr">[140]</xref>, <xref rid="bib0141" ref-type="bibr">[141]</xref> and pyrazinib <xref rid="bib0146" ref-type="bibr">[146]</xref> might have some promise as radiosensitisers. Research focused on development of therapeutics targeting radioresistance through rewiring of mitochondria dysfunctions and altered metabolism in cancer will translate to the development of novel radiosensitisers, with the ultimate goal of improving response to radiotherapy in cancer patients.</p></sec><sec id="sec0016a"><title>CRediT authorship contribution statement</title><p id="para0026a"><bold>Emma McCann:</bold> Investigation, Writing - original draft. <bold>Jacintha O'Sullivan:</bold> Conceptualization, Writing - review &#x00026; editing. <bold>Simone Marcone:</bold> Conceptualization, Writing - review &#x00026; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="para0027">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Shridhar</surname><given-names>R.</given-names></name><name><surname>Almhanna</surname><given-names>K.</given-names></name><name><surname>Meredith</surname><given-names>K.L.</given-names></name><name><surname>Biagioli</surname><given-names>M.C.</given-names></name><name><surname>Chuong</surname><given-names>M.D.</given-names></name><name><surname>Cruz</surname><given-names>A.</given-names></name><name><surname>Hoffe</surname><given-names>S.E.</given-names></name></person-group><article-title>Radiation therapy and esophageal cancer</article-title><source>Cancer Control</source><volume>20</volume><year>2013</year><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">23571700</pub-id></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>F.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Xiang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name></person-group><article-title>Role of metabolism in cancer cell radioresistance and radiosensitization methods</article-title><source>J. Exp. Clin. Cancer Res.</source><volume>37</volume><year>2018</year><fpage>87</fpage><pub-id pub-id-type="pmid">29688867</pub-id></element-citation></ref><ref id="bib0003"><label>3</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Seyfried</surname><given-names>T.N.</given-names></name><name><surname>Huysentruyt</surname><given-names>L.C.</given-names></name></person-group><article-title>On the origin of cancer metastasis</article-title><source>Crit. Rev. Oncog.</source><volume>18</volume><year>2013</year><fpage>43</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">23237552</pub-id></element-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Seo</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Seong</surname><given-names>K.M.</given-names></name><name><surname>Youn</surname><given-names>H.</given-names></name><name><surname>Youn</surname><given-names>B.</given-names></name></person-group><article-title>Cellular Stress Responses in Radiotherapy</article-title><source>Cells</source><year>2019</year><fpage>8</fpage></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.S.</given-names></name><name><surname>Wang</surname><given-names>H.J.</given-names></name><name><surname>Qian</surname><given-names>H.L.</given-names></name></person-group><article-title>Biological effects of radiation on cancer cells</article-title><source>Mil. Med. Res.</source><volume>5</volume><year>2018</year><fpage>20</fpage><pub-id pub-id-type="pmid">29958545</pub-id></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>K.A.</given-names></name><name><surname>Chinnaiyan</surname><given-names>P.</given-names></name><name><surname>Fulp</surname><given-names>W.J.</given-names></name><name><surname>Eschrich</surname><given-names>S.</given-names></name><name><surname>Torres-Roca</surname><given-names>J.F.</given-names></name><name><surname>Caudell</surname><given-names>J.J.</given-names></name></person-group><article-title>The radiosensitivity index predicts for overall survival in glioblastoma</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>34414</fpage><lpage>34422</lpage><pub-id pub-id-type="pmid">26451615</pub-id></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Jameel</surname><given-names>J.K.</given-names></name><name><surname>Rao</surname><given-names>V.S.</given-names></name><name><surname>Cawkwell</surname><given-names>L.</given-names></name><name><surname>Drew</surname><given-names>P.J.</given-names></name></person-group><article-title>Radioresistance in carcinoma of the breast</article-title><source>Breast</source><volume>13</volume><year>2004</year><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">15563851</pub-id></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>T.N.</given-names></name><name><surname>Noonan</surname><given-names>N.</given-names></name><name><surname>Hollywood</surname><given-names>D.</given-names></name><name><surname>Kelly</surname><given-names>A.</given-names></name><name><surname>Keeling</surname><given-names>N.</given-names></name><name><surname>Hennessy</surname><given-names>T.P.</given-names></name></person-group><article-title>A comparison of multimodal therapy and surgery for esophageal adenocarcinoma</article-title><source>New Engl. J. Med.</source><volume>335</volume><year>1996</year><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">8672151</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Diehn</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>R.W.</given-names></name><name><surname>Lobo</surname><given-names>N.A.</given-names></name><name><surname>Kalisky</surname><given-names>T.</given-names></name><name><surname>Dorie</surname><given-names>M.J.</given-names></name><name><surname>Kulp</surname><given-names>A.N.</given-names></name><name><surname>Qian</surname><given-names>D.</given-names></name><name><surname>Lam</surname><given-names>J.S.</given-names></name><name><surname>Ailles</surname><given-names>L.E.</given-names></name><name><surname>Wong</surname><given-names>M.</given-names></name><name><surname>Joshua</surname><given-names>B.</given-names></name><name><surname>Kaplan</surname><given-names>M.J.</given-names></name><name><surname>Wapnir</surname><given-names>I.</given-names></name><name><surname>Dirbas</surname><given-names>F.M.</given-names></name><name><surname>Somlo</surname><given-names>G.</given-names></name><name><surname>Garberoglio</surname><given-names>C.</given-names></name><name><surname>Paz</surname><given-names>B.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Quake</surname><given-names>S.R.</given-names></name><name><surname>Brown</surname><given-names>J.M.</given-names></name><name><surname>Weissman</surname><given-names>I.L.</given-names></name><name><surname>Clarke</surname><given-names>M.F.</given-names></name></person-group><article-title>Association of reactive oxygen species levels and radioresistance in cancer stem cells</article-title><source>Nature</source><volume>458</volume><year>2009</year><fpage>780</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">19194462</pub-id></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>W.W.</given-names></name><name><surname>Banati</surname><given-names>R.B.</given-names></name></person-group><article-title>Effects of ionizing radiation on mitochondria</article-title><source>Free Radic. Biol. Med.</source><volume>65</volume><year>2013</year><fpage>607</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">23892359</pub-id></element-citation></ref><ref id="bib0011"><label>11</label><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>D.C.</given-names></name></person-group><article-title>Mitochondria and cancer</article-title><source>Nat. Rev. Cancer</source><volume>12</volume><year>2012</year><fpage>685</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">23001348</pub-id></element-citation></ref><ref id="bib0012"><label>12</label><element-citation publication-type="journal" id="sbref0012"><person-group person-group-type="author"><name><surname>Vakifahmetoglu-Norberg</surname><given-names>H.</given-names></name><name><surname>Ouchida</surname><given-names>A.T.</given-names></name><name><surname>Norberg</surname><given-names>E.</given-names></name></person-group><article-title>The role of mitochondria in metabolism and cell death</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>482</volume><year>2017</year><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">28212726</pub-id></element-citation></ref><ref id="bib0013"><label>13</label><mixed-citation publication-type="other" id="sbref0013">J.M. Berg, J.L. Tymoczko, L. Stryer, Biochemistry, W.H.Freeman, New York, 2007.</mixed-citation></ref><ref id="bib0014"><label>14</label><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>T.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Krelin</surname><given-names>Y.</given-names></name><name><surname>Shteinfer-Kuzmine</surname><given-names>A.</given-names></name><name><surname>Shoshan-Barmatz</surname><given-names>V.</given-names></name></person-group><article-title>Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States</article-title><source>Cancers (Basel)</source><year>2018</year><fpage>10</fpage></element-citation></ref><ref id="bib0015"><label>15</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Lynam-Lennon</surname><given-names>N.</given-names></name><name><surname>Maher</surname><given-names>S.G.</given-names></name><name><surname>Maguire</surname><given-names>A.</given-names></name><name><surname>Phelan</surname><given-names>J.</given-names></name><name><surname>Muldoon</surname><given-names>C.</given-names></name><name><surname>Reynolds</surname><given-names>J.V.</given-names></name><name><surname>O'Sullivan</surname><given-names>J.</given-names></name></person-group><article-title>Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma</article-title><source>PLoS ONE</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e100738</object-id></element-citation></ref><ref id="bib0016"><label>16</label><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><year>2011</year><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib0017"><label>17</label><element-citation publication-type="book" id="sbref0017"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O.H.</given-names></name><name><surname>Dickens</surname><given-names>F.</given-names></name><name><surname>Kaiser-Wilhelm-Institut f&#x000fc;r</surname><given-names>B.</given-names></name></person-group><chapter-title>The Metabolism of tumours; Investigations from the Kaiser Wilhelm Institute For biology, Berlin-Dahlem</chapter-title><year>1930</year><publisher-name>Constable &#x00026; Co. Ltd.</publisher-name><publisher-loc>London</publisher-loc></element-citation></ref><ref id="bib0018"><label>18</label><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>G.Y.</given-names></name><name><surname>Storz</surname><given-names>P.</given-names></name></person-group><article-title>Reactive oxygen species in cancer</article-title><source>Free Radic Res</source><volume>44</volume><year>2010</year><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">20370557</pub-id></element-citation></ref><ref id="bib0019"><label>19</label><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name></person-group><article-title>Mitochondrial dysfunctions regulated radioresistance through mitochondria-to-nucleus retrograde signaling pathway of NF-&#x003ba;B/PI3K/AKT2/mTOR</article-title><source>Radiat. Res.</source><volume>190</volume><year>2018</year><fpage>204</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">29863983</pub-id></element-citation></ref><ref id="bib0020"><label>20</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Ge</surname><given-names>Z.</given-names></name></person-group><article-title>Role of antioxidant enzymes on ionizing radiation resistance</article-title><source>Free Radic. Biol. Med.</source><volume>24</volume><year>1998</year><fpage>586</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">9559871</pub-id></element-citation></ref><ref id="bib0021"><label>21</label><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Lynam-Lennon</surname><given-names>N.</given-names></name><name><surname>Reynolds</surname><given-names>J.V.</given-names></name><name><surname>Pidgeon</surname><given-names>G.P.</given-names></name><name><surname>Lysaght</surname><given-names>J.</given-names></name><name><surname>Marignol</surname><given-names>L.</given-names></name><name><surname>Maher</surname><given-names>S.G.</given-names></name></person-group><article-title>Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma</article-title><source>Radiat. Res.</source><volume>174</volume><year>2010</year><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">21128793</pub-id></element-citation></ref><ref id="bib0022"><label>22</label><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Hanot</surname><given-names>M.</given-names></name><name><surname>Boivin</surname><given-names>A.</given-names></name><name><surname>Mal&#x000e9;sys</surname><given-names>C.</given-names></name><name><surname>Beuve</surname><given-names>M.</given-names></name><name><surname>Colliaux</surname><given-names>A.</given-names></name><name><surname>Foray</surname><given-names>N.</given-names></name><name><surname>Douki</surname><given-names>T.</given-names></name><name><surname>Ardail</surname><given-names>D.</given-names></name><name><surname>Rodriguez-Lafrasse</surname><given-names>C.</given-names></name></person-group><article-title>Glutathione depletion and carbon ion radiation potentiate clustered DNA lesions, cell death and prevent chromosomal changes in cancer cells progeny</article-title><source>PLoS ONE</source><volume>7</volume><year>2012</year><fpage>e44367</fpage><pub-id pub-id-type="pmid">23185232</pub-id></element-citation></ref><ref id="bib0023"><label>23</label><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Miura</surname><given-names>M.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name></person-group><article-title>Role of glutathione in the intrinsic radioresistance of cell lines from a mouse squamous cell carcinoma</article-title><source>Radiat. Res.</source><volume>126</volume><year>1991</year><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">2023994</pub-id></element-citation></ref><ref id="bib0024"><label>24</label><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhuo</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling</article-title><source>Br. J. Cancer</source><year>2020</year></element-citation></ref><ref id="bib0025"><label>25</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>K.</given-names></name><name><surname>Longo</surname><given-names>D.L.</given-names></name><name><surname>Oppenheim</surname><given-names>J.J.</given-names></name><name><surname>Matsushima</surname><given-names>K.</given-names></name></person-group><article-title>Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation</article-title><source>FASEB J.</source><volume>7</volume><year>1993</year><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">8440412</pub-id></element-citation></ref><ref id="bib0026"><label>26</label><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name><surname>Kalen</surname><given-names>A.L.</given-names></name><name><surname>Sarsour</surname><given-names>E.H.</given-names></name><name><surname>Venkataraman</surname><given-names>S.</given-names></name><name><surname>Goswami</surname><given-names>P.C.</given-names></name></person-group><article-title>Mn-superoxide dismutase overexpression enhances G2 accumulation and radioresistance in human oral squamous carcinoma cells</article-title><source>Antioxid. Redox Signal</source><volume>8</volume><year>2006</year><fpage>1273</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">16910775</pub-id></element-citation></ref><ref id="bib0027"><label>27</label><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>C.J.</given-names></name><name><surname>Goswami</surname><given-names>P.C.</given-names></name></person-group><article-title>Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells</article-title><source>Cancer Biol. Ther.</source><volume>7</volume><year>2008</year><fpage>1271</fpage><lpage>1279</lpage><pub-id pub-id-type="pmid">18497575</pub-id></element-citation></ref><ref id="bib0028"><label>28</label><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Melendez</surname><given-names>J.A.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Nie</surname><given-names>S.</given-names></name><name><surname>Pearce</surname><given-names>L.</given-names></name><name><surname>Peterson</surname><given-names>J.</given-names></name><name><surname>Franicola</surname><given-names>D.</given-names></name><name><surname>Dixon</surname><given-names>T.</given-names></name><name><surname>Greenberger</surname><given-names>B.A.</given-names></name><name><surname>Komanduri</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name></person-group><article-title>Mitochondrial targeting of a catalase transgene product by plasmid liposomes increases radioresistance <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Radiat. Res.</source><volume>171</volume><year>2009</year><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">19580494</pub-id></element-citation></ref><ref id="bib0029"><label>29</label><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Melendez</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Franicola</surname><given-names>D.</given-names></name><name><surname>Smith</surname><given-names>T.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name></person-group><article-title>Radioresistance induced by MnSOD overexpression in 32DCl 3murine hematopoietic progenitor cells is further increased by localization of a catalase transgene product to the mitochondria</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><volume>69</volume><year>2007</year><fpage>S610</fpage></element-citation></ref><ref id="bib0030"><label>30</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Wegner</surname><given-names>R.</given-names></name><name><surname>Kanai</surname><given-names>A.J.</given-names></name><name><surname>Kagan</surname><given-names>V.</given-names></name><name><surname>Greenberger</surname><given-names>E.E.</given-names></name><name><surname>Nie</surname><given-names>S.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name></person-group><article-title>Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthotopic tumors</article-title><source>Radiat. Res.</source><volume>167</volume><year>2007</year><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">17316075</pub-id></element-citation></ref><ref id="bib0031"><label>31</label><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>A.J.</given-names></name><name><surname>Zeidel</surname><given-names>M.L.</given-names></name><name><surname>Lavelle</surname><given-names>J.P.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name><name><surname>Birder</surname><given-names>L.A.</given-names></name><name><surname>de Groat</surname><given-names>W.C.</given-names></name><name><surname>Apodaca</surname><given-names>G.L.</given-names></name><name><surname>Meyers</surname><given-names>S.A.</given-names></name><name><surname>Ramage</surname><given-names>R.</given-names></name><name><surname>Epperly</surname><given-names>M.W</given-names></name></person-group><article-title>Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis</article-title><source>Am. J. Physiol. Renal Physiol.</source><volume>283</volume><year>2002</year><fpage>F1304</fpage><lpage>F1312</lpage><pub-id pub-id-type="pmid">12426235</pub-id></element-citation></ref><ref id="bib0032"><label>32</label><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>M.</given-names></name><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Agarwal</surname><given-names>A.</given-names></name><name><surname>Nie</surname><given-names>S.</given-names></name><name><surname>Hricisak</surname><given-names>L.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name></person-group><article-title>Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage</article-title><source>Gene. Ther.</source><volume>12</volume><year>2005</year><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">15750616</pub-id></element-citation></ref><ref id="bib0033"><label>33</label><element-citation publication-type="journal" id="sbref0033"><person-group person-group-type="author"><name><surname>Stickle</surname><given-names>R.L.</given-names></name><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Klein</surname><given-names>E.</given-names></name><name><surname>Bray</surname><given-names>J.A.</given-names></name><name><surname>Greenberger</surname><given-names>J.S.</given-names></name></person-group><article-title>Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene</article-title><source>Radiat. Oncol. Investig.</source><volume>7</volume><year>1999</year><fpage>204</fpage><lpage>217</lpage></element-citation></ref><ref id="bib0034"><label>34</label><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name><surname>Niranjan</surname><given-names>B.G.</given-names></name><name><surname>Bhat</surname><given-names>N.K.</given-names></name><name><surname>Avadhani</surname><given-names>N.G.</given-names></name></person-group><article-title>Preferential attack of mitochondrial DNA by aflatoxin B1 during hepatocarcinogenesis</article-title><source>Science</source><volume>215</volume><year>1982</year><fpage>73</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">6797067</pub-id></element-citation></ref><ref id="bib0035"><label>35</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Backer</surname><given-names>J.M.</given-names></name><name><surname>Weinstein</surname><given-names>I.B.</given-names></name></person-group><article-title>Mitochondrial DNA is a major cellular target for a dihydrodiol-epoxide derivative of benzo[<italic>a</italic>]pyrene</article-title><source>Science</source><volume>209</volume><year>1980</year><fpage>297</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">6770466</pub-id></element-citation></ref><ref id="bib0036"><label>36</label><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name><surname>LeDoux</surname><given-names>S.P.</given-names></name><name><surname>Driggers</surname><given-names>W.J.</given-names></name><name><surname>Hollensworth</surname><given-names>B.S.</given-names></name><name><surname>Wilson</surname><given-names>G.L.</given-names></name></person-group><article-title>Repair of alkylation and oxidative damage in mitochondrial DNA</article-title><source>Mutat. Res.</source><volume>434</volume><year>1999</year><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">10486589</pub-id></element-citation></ref><ref id="bib0037"><label>37</label><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name><surname>Bohr</surname><given-names>V.A.</given-names></name><name><surname>Stevnsner</surname><given-names>T.</given-names></name><name><surname>de Souza-Pinto</surname><given-names>N.C.</given-names></name></person-group><article-title>Mitochondrial DNA repair of oxidative damage in mammalian cells</article-title><source>Gene</source><volume>286</volume><year>2002</year><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">11943468</pub-id></element-citation></ref><ref id="bib0038"><label>38</label><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name><surname>Pinz</surname><given-names>K.G.</given-names></name><name><surname>Bogenhagen</surname><given-names>D.F.</given-names></name></person-group><article-title>Efficient repair of abasic sites in DNA by mitochondrial enzymes</article-title><source>Mol. Cell Biol.</source><volume>18</volume><year>1998</year><fpage>1257</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">9488440</pub-id></element-citation></ref><ref id="bib0039"><label>39</label><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name><surname>LeDoux</surname><given-names>S.P.</given-names></name><name><surname>Wilson</surname><given-names>G.L.</given-names></name></person-group><article-title>Base excision repair of mitochondrial DNA damage in mammalian cells</article-title><source>Prog. Nucleic Acid Res. Mol. Biol.</source><volume>68</volume><year>2001</year><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">11554303</pub-id></element-citation></ref><ref id="bib0040"><label>40</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Zinovkina</surname><given-names>L.A.</given-names></name></person-group><article-title>Mechanisms of Mitochondrial DNA Repair in Mammals</article-title><source>Biochemistry (Mosc)</source><volume>83</volume><year>2018</year><fpage>233</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">29625543</pub-id></element-citation></ref><ref id="bib0041"><label>41</label><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>R.S.Y.</given-names></name></person-group><article-title>Apoptosis in cancer: from pathogenesis to treatment</article-title><source>J. Exp. Clin. Cancer Res. CR</source><volume>30</volume><year>2011</year><comment>87-87</comment></element-citation></ref><ref id="bib0042"><label>42</label><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>J.W.</given-names></name><name><surname>Cheon</surname><given-names>G.J.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>Y.S.</given-names></name><name><surname>Choi</surname><given-names>E.Y.</given-names></name><name><surname>Yoon</surname><given-names>B.H.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name><name><surname>Chung</surname><given-names>M.H.</given-names></name></person-group><article-title>Radiation sensitivity depends on OGG1 activity status in human leukemia cell lines</article-title><source>Free Radic. Biol. Med.</source><volume>32</volume><year>2002</year><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">11827746</pub-id></element-citation></ref><ref id="bib0043"><label>43</label><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name><surname>Ramdzan</surname><given-names>Z.M.</given-names></name><name><surname>Pal</surname><given-names>R.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Leduy</surname><given-names>L.</given-names></name><name><surname>B&#x000e9;rub&#x000e9;</surname><given-names>G.</given-names></name><name><surname>Davoudi</surname><given-names>S.</given-names></name><name><surname>Vadnais</surname><given-names>C.</given-names></name><name><surname>Nepveu</surname><given-names>A.</given-names></name></person-group><article-title>The function of CUX1 in oxidative DNA damage repair is needed to prevent premature senescence of mouse embryo fibroblasts</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>3613</fpage><lpage>3626</lpage><pub-id pub-id-type="pmid">25682875</pub-id></element-citation></ref><ref id="bib0044"><label>44</label><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name><surname>Ramdzan</surname><given-names>Z.M.</given-names></name><name><surname>Vadnais</surname><given-names>C.</given-names></name><name><surname>Pal</surname><given-names>R.</given-names></name><name><surname>Vandal</surname><given-names>G.</given-names></name><name><surname>Cadieux</surname><given-names>C.</given-names></name><name><surname>Leduy</surname><given-names>L.</given-names></name><name><surname>Davoudi</surname><given-names>S.</given-names></name><name><surname>Hulea</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Karnezis</surname><given-names>A.N.</given-names></name><name><surname>Paquet</surname><given-names>M.</given-names></name><name><surname>Dankort</surname><given-names>D.</given-names></name><name><surname>Nepveu</surname><given-names>A.</given-names></name></person-group><article-title>RAS transformation requires CUX1-dependent repair of oxidative DNA damage</article-title><source>PLoS Biol.</source><volume>12</volume><year>2014</year><object-id pub-id-type="publisher-id">e1001807</object-id></element-citation></ref><ref id="bib0045"><label>45</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>R.</given-names></name><name><surname>Ramdzan</surname><given-names>Z.M.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Duquette</surname><given-names>P.M.</given-names></name><name><surname>Marcotte</surname><given-names>R.</given-names></name><name><surname>Leduy</surname><given-names>L.</given-names></name><name><surname>Davoudi</surname><given-names>S.</given-names></name><name><surname>Lamarche-Vane</surname><given-names>N.</given-names></name><name><surname>Iulianella</surname><given-names>A.</given-names></name><name><surname>Nepveu</surname><given-names>A.</given-names></name></person-group><article-title>CUX2 protein functions as an accessory factor in the repair of oxidative DNA damage</article-title><source>J. Biol. Chem.</source><volume>290</volume><year>2015</year><fpage>22520</fpage><lpage>22531</lpage><pub-id pub-id-type="pmid">26221032</pub-id></element-citation></ref><ref id="bib0046"><label>46</label><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name><surname>Ramdzan</surname><given-names>Z.M.</given-names></name><name><surname>Ginjala</surname><given-names>V.</given-names></name><name><surname>Pinder</surname><given-names>J.B.</given-names></name><name><surname>Chung</surname><given-names>D.</given-names></name><name><surname>Donovan</surname><given-names>C.M.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Leduy</surname><given-names>L.</given-names></name><name><surname>Dellaire</surname><given-names>G.</given-names></name><name><surname>Ganesan</surname><given-names>S.</given-names></name><name><surname>Nepveu</surname><given-names>A.</given-names></name></person-group><article-title>The DNA repair function of CUX1 contributes to radioresistance</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>19021</fpage><lpage>19038</lpage><pub-id pub-id-type="pmid">28147323</pub-id></element-citation></ref><ref id="bib0047"><label>47</label><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name><surname>Ripka</surname><given-names>S.</given-names></name><name><surname>Neesse</surname><given-names>A.</given-names></name><name><surname>Riedel</surname><given-names>J.</given-names></name><name><surname>Bug</surname><given-names>E.</given-names></name><name><surname>Aigner</surname><given-names>A.</given-names></name><name><surname>Poulsom</surname><given-names>R.</given-names></name><name><surname>Fulda</surname><given-names>S.</given-names></name><name><surname>Neoptolemos</surname><given-names>J.</given-names></name><name><surname>Greenhalf</surname><given-names>W.</given-names></name><name><surname>Barth</surname><given-names>P.</given-names></name><name><surname>Gress</surname><given-names>T.M.</given-names></name><name><surname>Michl</surname><given-names>P.</given-names></name></person-group><article-title>CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer</article-title><source>Gut</source><volume>59</volume><year>2010</year><fpage>1101</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">20442202</pub-id></element-citation></ref><ref id="bib0048"><label>48</label><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name><surname>Cancer Genome Atlas</surname><given-names>N.</given-names></name></person-group><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><volume>487</volume><year>2012</year><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">22810696</pub-id></element-citation></ref><ref id="bib0049"><label>49</label><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>T.</given-names></name><name><surname>Barnes</surname><given-names>D.E.</given-names></name></person-group><article-title>Repair of endogenous DNA damage</article-title><source>Cold Spring Harb. Symp. Quant. Biol.</source><volume>65</volume><year>2000</year><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">12760027</pub-id></element-citation></ref><ref id="bib0050"><label>50</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Ramdzan</surname><given-names>Z.M.</given-names></name><name><surname>Pal</surname><given-names>R.</given-names></name><name><surname>Kaur</surname><given-names>S.</given-names></name><name><surname>Leduy</surname><given-names>L.</given-names></name><name><surname>Berube</surname><given-names>G.</given-names></name><name><surname>Davoudi</surname><given-names>S.</given-names></name><name><surname>Vadnais</surname><given-names>C.</given-names></name><name><surname>Nepveu</surname><given-names>A.</given-names></name></person-group><article-title>The function of CUX1 in oxidative DNA damage repair is needed to prevent premature senescence of mouse embryo fibroblasts</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>3613</fpage><lpage>3626</lpage><pub-id pub-id-type="pmid">25682875</pub-id></element-citation></ref><ref id="bib0051"><label>51</label><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Birsoy</surname><given-names>K.</given-names></name><name><surname>Hughes</surname><given-names>N.W.</given-names></name><name><surname>Krupczak</surname><given-names>K.M.</given-names></name><name><surname>Post</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>J.J.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Sabatini</surname><given-names>D.M.</given-names></name></person-group><article-title>Identification and characterization of essential genes in the human genome</article-title><source>Science</source><volume>350</volume><year>2015</year><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">26472758</pub-id></element-citation></ref><ref id="bib0052"><label>52</label><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>T.</given-names></name></person-group><article-title>Human single-stranded DNA binding proteins: guardians of genome stability</article-title><source>Acta Biochim. Biophys. Sin. (Shanghai</source><volume>48</volume><year>2016</year><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">27217471</pub-id></element-citation></ref><ref id="bib0053"><label>53</label><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name><surname>Shapovalov</surname><given-names>Y.</given-names></name><name><surname>Hoffman</surname><given-names>D.</given-names></name><name><surname>Zuch</surname><given-names>D.</given-names></name><name><surname>de Mesy Bentley</surname><given-names>K.L.</given-names></name><name><surname>Eliseev</surname><given-names>R.A.</given-names></name></person-group><article-title>Mitochondrial dysfunction in cancer cells due to aberrant mitochondrial replication</article-title><source>J. Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>22331</fpage><lpage>22338</lpage><pub-id pub-id-type="pmid">21536680</pub-id></element-citation></ref><ref id="bib0054"><label>54</label><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name></person-group><article-title>Downregulation of mitochondrial single stranded DNA binding protein (SSBP1) induces mitochondrial dysfunction and increases the radiosensitivity in non-small cell lung cancer cells</article-title><source>J. Cancer</source><volume>8</volume><year>2017</year><fpage>1400</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">28638454</pub-id></element-citation></ref><ref id="bib0055"><label>55</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Vignard</surname><given-names>J.</given-names></name><name><surname>Mirey</surname><given-names>G.</given-names></name><name><surname>Salles</surname><given-names>B.</given-names></name></person-group><article-title>Ionizing-radiation induced DNA double-strand breaks: a direct and indirect lighting up</article-title><source>Radiother. Oncol.</source><volume>108</volume><year>2013</year><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">23849169</pub-id></element-citation></ref><ref id="bib0056"><label>56</label><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Makrigiorgos</surname><given-names>G.M.</given-names></name><name><surname>Price</surname><given-names>B.D.</given-names></name></person-group><article-title>Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>344</volume><year>2006</year><fpage>821</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">16631604</pub-id></element-citation></ref><ref id="bib0057"><label>57</label><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name><surname>Squatrito</surname><given-names>M.</given-names></name><name><surname>Brennan</surname><given-names>C.W.</given-names></name><name><surname>Helmy</surname><given-names>K.</given-names></name><name><surname>Huse</surname><given-names>J.T.</given-names></name><name><surname>Petrini</surname><given-names>J.H.</given-names></name><name><surname>Holland</surname><given-names>E.C.</given-names></name></person-group><article-title>Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas</article-title><source>Cancer Cell</source><volume>18</volume><year>2010</year><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">21156285</pub-id></element-citation></ref><ref id="bib0058"><label>58</label><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name><surname>You</surname><given-names>W.C.</given-names></name><name><surname>Chiou</surname><given-names>S.H.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Chiang</surname><given-names>S.F.</given-names></name><name><surname>Yang</surname><given-names>C.L.</given-names></name><name><surname>Sudhakar</surname><given-names>J.N.</given-names></name><name><surname>Lin</surname><given-names>T.Y.</given-names></name><name><surname>Chiang</surname><given-names>I.P.</given-names></name><name><surname>Shen</surname><given-names>C.C.</given-names></name><name><surname>Cheng</surname><given-names>W.Y.</given-names></name><name><surname>Lin</surname><given-names>J.C.</given-names></name><name><surname>Shieh</surname><given-names>S.H.</given-names></name><name><surname>Chow</surname><given-names>K.C.</given-names></name></person-group><article-title>Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma</article-title><source>Neuro Oncol.</source><volume>15</volume><year>2013</year><fpage>1342</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">24057885</pub-id></element-citation></ref><ref id="bib0059"><label>59</label><mixed-citation publication-type="other" id="sbref0059">S. De Vleeschouwer, Glioblastoma, 2017.</mixed-citation></ref><ref id="bib0060"><label>60</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Fouad</surname><given-names>Y.A.</given-names></name><name><surname>Aanei</surname><given-names>C.</given-names></name></person-group><article-title>Revisiting the hallmarks of cancer</article-title><source>Am. J. Cancer Res.</source><volume>7</volume><year>2017</year><fpage>1016</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">28560055</pub-id></element-citation></ref><ref id="bib0061"><label>61</label><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name></person-group><article-title>Radiation induces apoptosis primarily through the intrinsic pathway in mammalian cells</article-title><source>Cell Signal</source><volume>62</volume><year>2019</year><object-id pub-id-type="publisher-id">109337</object-id></element-citation></ref><ref id="bib0062"><label>62</label><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name><surname>Momcilovic</surname><given-names>M.</given-names></name><name><surname>Shackelford</surname><given-names>D.B.</given-names></name></person-group><article-title>Targeting LKB1 in cancer - exposing and exploiting vulnerabilities</article-title><source>Br. J. Cancer</source><volume>113</volume><year>2015</year><fpage>574</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">26196184</pub-id></element-citation></ref><ref id="bib0063"><label>63</label><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>R.Y.</given-names></name><name><surname>Li</surname><given-names>H.B.</given-names></name></person-group><article-title>Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function</article-title><source>Int. J. Mol. Sci.</source><volume>15</volume><year>2014</year><fpage>16698</fpage><lpage>16718</lpage><pub-id pub-id-type="pmid">25244018</pub-id></element-citation></ref><ref id="bib0064"><label>64</label><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name><surname>Shackelford</surname><given-names>D.B.</given-names></name><name><surname>Shaw</surname><given-names>R.J.</given-names></name></person-group><article-title>The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nature reviews</article-title><source>Cancer</source><volume>9</volume><year>2009</year><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">19629071</pub-id></element-citation></ref><ref id="bib0065"><label>65</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Saigusa</surname><given-names>S.</given-names></name><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Toiyama</surname><given-names>Y.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name><name><surname>Okugawa</surname><given-names>Y.</given-names></name><name><surname>Okigami</surname><given-names>M.</given-names></name><name><surname>Hiro</surname><given-names>J.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Mohri</surname><given-names>Y.</given-names></name><name><surname>Kusunoki</surname><given-names>M.</given-names></name></person-group><article-title>Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy</article-title><source>J. Cancer Res. Clin. Oncol.</source><volume>139</volume><year>2013</year><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">22986809</pub-id></element-citation></ref><ref id="bib0066"><label>66</label><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name></person-group><article-title>LKB1 promotes radioresistance in esophageal cancer cells exposed to radiation, by suppression of apoptosis and activation of autophagy via the AMPK pathway</article-title><source>Mol. Med. Rep.</source><volume>16</volume><year>2017</year><fpage>2205</fpage><lpage>2210</lpage><pub-id pub-id-type="pmid">28656285</pub-id></element-citation></ref><ref id="bib0067"><label>67</label><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>G.L.</given-names></name><name><surname>Lapadat</surname><given-names>R.</given-names></name></person-group><article-title>Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases</article-title><source>Science</source><volume>298</volume><year>2002</year><fpage>1911</fpage><lpage>1912</lpage><pub-id pub-id-type="pmid">12471242</pub-id></element-citation></ref><ref id="bib0068"><label>68</label><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>N.</given-names></name><name><surname>Nantajit</surname><given-names>D.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.J.</given-names></name></person-group><article-title>Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulation</article-title><source>J. Biol. Chem.</source><volume>283</volume><year>2008</year><fpage>21011</fpage><lpage>21023</lpage><pub-id pub-id-type="pmid">18508759</pub-id></element-citation></ref><ref id="bib0069"><label>69</label><element-citation publication-type="book" id="sbref0069"><comment>edited by</comment><person-group person-group-type="editor"><name><surname>Pezzella</surname><given-names>Francesco</given-names></name><name><surname>Tavassoli</surname><given-names>Mahvash</given-names></name><name><surname>Kerr</surname><given-names>David J</given-names></name></person-group><source>Oxford Textbook of Cancer Biology</source><year>2019</year><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford</publisher-loc><comment>edited bypp. 0-0</comment></element-citation></ref><ref id="bib0070"><label>70</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>H.</given-names></name><name><surname>Furihata</surname><given-names>M.</given-names></name><name><surname>Ohtsuki</surname><given-names>Y.</given-names></name><name><surname>Ogoshi</surname><given-names>S.</given-names></name></person-group><article-title>Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma</article-title><source>Virchows Archiv</source><volume>434</volume><year>1999</year><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">10071250</pub-id></element-citation></ref><ref id="bib0071"><label>71</label><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name><surname>Soria</surname><given-names>J.C.</given-names></name><name><surname>Jang</surname><given-names>S.J.</given-names></name><name><surname>Khuri</surname><given-names>F.R.</given-names></name><name><surname>Hassan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Hong</surname><given-names>W.K.</given-names></name><name><surname>Mao</surname><given-names>L.</given-names></name></person-group><article-title>Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication</article-title><source>Cancer Res.</source><volume>60</volume><year>2000</year><fpage>4000</fpage><pub-id pub-id-type="pmid">10945597</pub-id></element-citation></ref><ref id="bib0072"><label>72</label><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name><surname>Kushner</surname><given-names>J.</given-names></name><name><surname>Bradley</surname><given-names>G.</given-names></name><name><surname>Young</surname><given-names>B.</given-names></name><name><surname>Jordan</surname><given-names>R.C.K.</given-names></name></person-group><article-title>Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma</article-title><source>J. Oral Pathol. Med.</source><volume>28</volume><year>1999</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9950254</pub-id></element-citation></ref><ref id="bib0073"><label>73</label><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name><surname>Kallakury</surname><given-names>B.V.S.</given-names></name><name><surname>Sheehan</surname><given-names>C.E.</given-names></name><name><surname>Rhee</surname><given-names>S.J.</given-names></name><name><surname>Fisher</surname><given-names>H.A.G.</given-names></name><name><surname>Kaufman</surname><given-names>R.P.</given-names></name><name><surname>Rifkin</surname><given-names>M.D.</given-names></name><name><surname>Ross</surname><given-names>J.S.</given-names></name></person-group><article-title>The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma</article-title><source>Cancer</source><volume>85</volume><year>1999</year><fpage>1569</fpage><lpage>1576</lpage><pub-id pub-id-type="pmid">10193948</pub-id></element-citation></ref><ref id="bib0074"><label>74</label><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>H.</given-names></name><name><surname>Koizumi</surname><given-names>H.</given-names></name><name><surname>Uchikoshi</surname><given-names>T.</given-names></name></person-group><article-title>Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses</article-title><source>Am. J. Pathol.</source><volume>150</volume><year>1997</year><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9006317</pub-id></element-citation></ref><ref id="bib0075"><label>75</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>K.</given-names></name><name><surname>Jordan</surname><given-names>R.C.</given-names></name><name><surname>Ang</surname><given-names>L.C.</given-names></name><name><surname>Taylor</surname><given-names>M.</given-names></name><name><surname>Young</surname><given-names>B.</given-names></name></person-group><article-title>Overexpression of cyclin A and cyclin B1 proteins in astrocytomas</article-title><source>Arch. Pathol. Lab. Med.</source><volume>124</volume><year>2000</year><fpage>216</fpage><pub-id pub-id-type="pmid">10656729</pub-id></element-citation></ref><ref id="bib0076"><label>76</label><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S.K.</given-names></name><name><surname>Weston</surname><given-names>A.P.</given-names></name><name><surname>Zoubine</surname><given-names>M.N.</given-names></name><name><surname>Campbell</surname><given-names>D.R.</given-names></name><name><surname>Cherian</surname><given-names>R.</given-names></name></person-group><article-title>Expression of Cdc2 and Cyclin B1 in Helicobacter pylori-Associated Gastric MALT and MALT Lymphoma: relationship to Cell Death, Proliferation, and Transformation</article-title><source>Am. J. Pathol.</source><volume>156</volume><year>2000</year><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">10623670</pub-id></element-citation></ref><ref id="bib0077"><label>77</label><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name><surname>Cloos</surname><given-names>C.R.</given-names></name><name><surname>Daniels</surname><given-names>D.H.</given-names></name><name><surname>Kalen</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>K.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Goswami</surname><given-names>P.C.</given-names></name><name><surname>Cullen</surname><given-names>J.J.</given-names></name></person-group><article-title>Mitochondrial DNA depletion induces radioresistance by suppressing G2 checkpoint activation in human pancreatic cancer cells</article-title><source>Radiat. Res.</source><volume>171</volume><year>2009</year><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">19580493</pub-id></element-citation></ref><ref id="bib0078"><label>78</label><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name><surname>Muschel</surname><given-names>R.J.</given-names></name><name><surname>Zhang</surname><given-names>H.B.</given-names></name><name><surname>Iliakis</surname><given-names>G.</given-names></name><name><surname>McKenna</surname><given-names>W.G.</given-names></name></person-group><article-title>Cyclin B expression in HeLa cells during the G2 block induced by ionizing radiation</article-title><source>Cancer Res</source><volume>51</volume><year>1991</year><fpage>5113</fpage><lpage>5117</lpage><pub-id pub-id-type="pmid">1833048</pub-id></element-citation></ref><ref id="bib0079"><label>79</label><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name><surname>Lombard</surname><given-names>D.B.</given-names></name><name><surname>Tishkoff</surname><given-names>D.X.</given-names></name><name><surname>Bao</surname><given-names>J.</given-names></name></person-group><article-title>Mitochondrial sirtuins in the regulation of mitochondrial activity and metabolic adaptation</article-title><source>Handb. Exp. Pharmacol.</source><volume>206</volume><year>2011</year><fpage>163</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">21879450</pub-id></element-citation></ref><ref id="bib0080"><label>80</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Candas</surname><given-names>D.</given-names></name><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Eldridge</surname><given-names>A.</given-names></name><name><surname>Zou</surname><given-names>J.X.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Juma</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>R.F.</given-names></name><name><surname>Perks</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>L.Q.</given-names></name><name><surname>Vaughan</surname><given-names>A.T.</given-names></name><name><surname>Hai</surname><given-names>C.X.</given-names></name><name><surname>Gius</surname><given-names>D.R.</given-names></name><name><surname>Li</surname><given-names>J.J.</given-names></name></person-group><article-title>CDK1-Mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance</article-title><source>Mol. Cancer Ther.</source><volume>14</volume><year>2015</year><fpage>2090</fpage><lpage>2102</lpage><pub-id pub-id-type="pmid">26141949</pub-id></element-citation></ref><ref id="bib0081"><label>81</label><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Mitochondrial retrograde signalling and metabolic alterations in the tumour microenvironment</article-title><source>Cells</source><year>2019</year><fpage>8</fpage></element-citation></ref><ref id="bib0082"><label>82</label><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name><surname>Guha</surname><given-names>M.</given-names></name><name><surname>Avadhani</surname><given-names>N.G.</given-names></name></person-group><article-title>Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics</article-title><source>Mitochondrion</source><volume>13</volume><year>2013</year><fpage>577</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">24004957</pub-id></element-citation></ref><ref id="bib0083"><label>83</label><element-citation publication-type="journal" id="sbref0083"><person-group person-group-type="author"><name><surname>Zorova</surname><given-names>L.D.</given-names></name><name><surname>Popkov</surname><given-names>V.A.</given-names></name><name><surname>Plotnikov</surname><given-names>E.Y.</given-names></name><name><surname>Silachev</surname><given-names>D.N.</given-names></name><name><surname>Pevzner</surname><given-names>I.B.</given-names></name><name><surname>Jankauskas</surname><given-names>S.S.</given-names></name><name><surname>Babenko</surname><given-names>V.A.</given-names></name><name><surname>Zorov</surname><given-names>S.D.</given-names></name><name><surname>Balakireva</surname><given-names>A.V.</given-names></name><name><surname>Juhaszova</surname><given-names>M.</given-names></name><name><surname>Sollott</surname><given-names>S.J.</given-names></name><name><surname>Zorov</surname><given-names>D.B.</given-names></name></person-group><article-title>Mitochondrial membrane potential</article-title><source>Anal. Biochem.</source><volume>552</volume><year>2018</year><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">28711444</pub-id></element-citation></ref><ref id="bib0084"><label>84</label><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Q.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression</article-title><source>Toxicol. Lett.</source><volume>224</volume><year>2014</year><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">24459703</pub-id></element-citation></ref><ref id="bib0085"><label>85</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.L.</given-names></name><name><surname>Chang</surname><given-names>J.T.</given-names></name><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Fan</surname><given-names>K.H.</given-names></name><name><surname>Lu</surname><given-names>Y.C.</given-names></name><name><surname>Li</surname><given-names>Y.C.</given-names></name><name><surname>Chiang</surname><given-names>C.H.</given-names></name><name><surname>You</surname><given-names>G.R.</given-names></name><name><surname>Chen</surname><given-names>H.Y.</given-names></name><name><surname>Cheng</surname><given-names>A.J.</given-names></name></person-group><article-title>GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMAD-associated signaling pathway</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>1508</fpage><lpage>1528</lpage><pub-id pub-id-type="pmid">27903972</pub-id></element-citation></ref><ref id="bib0086"><label>86</label><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Zou</surname><given-names>F.</given-names></name></person-group><article-title>Mitochondrial KATP Channels Control Glioma Radioresistance by Regulating ROS-Induced ERK Activation</article-title><source>Mol. Neurobiol.</source><volume>52</volume><year>2015</year><fpage>626</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">25249341</pub-id></element-citation></ref><ref id="bib0087"><label>87</label><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name><surname>Shoshan-Barmatz</surname><given-names>V.</given-names></name><name><surname>Ben-Hail</surname><given-names>D.</given-names></name><name><surname>Admoni</surname><given-names>L.</given-names></name><name><surname>Krelin</surname><given-names>Y.</given-names></name><name><surname>Tripathi</surname><given-names>S.S.</given-names></name></person-group><article-title>The mitochondrial voltage-dependent anion channel 1 in tumor cells</article-title><source>Biochimica et Biophysica Acta (BBA) - Biomembranes</source><volume>1848</volume><year>2015</year><fpage>2547</fpage><lpage>2575</lpage><pub-id pub-id-type="pmid">25448878</pub-id></element-citation></ref><ref id="bib0088"><label>88</label><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>G.J.</given-names></name></person-group><article-title>Metabolic reprogramming: the emerging concept and associated therapeutic strategies</article-title><source>J. Exp. Clin. Cancer Res.</source><volume>34</volume><year>2015</year><fpage>111</fpage><pub-id pub-id-type="pmid">26445347</pub-id></element-citation></ref><ref id="bib0089"><label>89</label><element-citation publication-type="journal" id="sbref0089"><person-group person-group-type="author"><name><surname>Priolo</surname><given-names>C.</given-names></name><name><surname>Pyne</surname><given-names>S.</given-names></name><name><surname>Rose</surname><given-names>J.</given-names></name><name><surname>Regan</surname><given-names>E.R.</given-names></name><name><surname>Zadra</surname><given-names>G.</given-names></name><name><surname>Photopoulos</surname><given-names>C.</given-names></name><name><surname>Cacciatore</surname><given-names>S.</given-names></name><name><surname>Schultz</surname><given-names>D.</given-names></name><name><surname>Scaglia</surname><given-names>N.</given-names></name><name><surname>McDunn</surname><given-names>J.</given-names></name><name><surname>De Marzo</surname><given-names>A.M.</given-names></name><name><surname>Loda</surname><given-names>M.</given-names></name></person-group><article-title>AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer</article-title><source>Cancer Res.</source><volume>74</volume><year>2014</year><fpage>7198</fpage><lpage>7204</lpage><pub-id pub-id-type="pmid">25322691</pub-id></element-citation></ref><ref id="bib0090"><label>90</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Du</surname><given-names>Y.E.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Wen</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>25755</fpage><lpage>25769</lpage><pub-id pub-id-type="pmid">26342198</pub-id></element-citation></ref><ref id="bib0091"><label>91</label><element-citation publication-type="journal" id="sbref0091"><person-group person-group-type="author"><name><surname>Pitroda</surname><given-names>S.P.</given-names></name><name><surname>Wakim</surname><given-names>B.T.</given-names></name><name><surname>Sood</surname><given-names>R.F.</given-names></name><name><surname>Beveridge</surname><given-names>M.G.</given-names></name><name><surname>Beckett</surname><given-names>M.A.</given-names></name><name><surname>MacDermed</surname><given-names>D.M.</given-names></name><name><surname>Weichselbaum</surname><given-names>R.R.</given-names></name><name><surname>Khodarev</surname><given-names>N.N.</given-names></name></person-group><article-title>STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect</article-title><source>BMC Med.</source><volume>7</volume><year>2009</year><fpage>68</fpage><pub-id pub-id-type="pmid">19891767</pub-id></element-citation></ref><ref id="bib0092"><label>92</label><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression</article-title><source>Cell Mol. Life Sci.</source><volume>73</volume><year>2016</year><fpage>377</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">26499846</pub-id></element-citation></ref><ref id="bib0093"><label>93</label><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name><surname>Mueckler</surname><given-names>M.</given-names></name><name><surname>Thorens</surname><given-names>B.</given-names></name></person-group><article-title>The SLC2 (GLUT) family of membrane transporters</article-title><source>Mol. Aspects Med.</source><volume>34</volume><year>2013</year><fpage>121</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">23506862</pub-id></element-citation></ref><ref id="bib0094"><label>94</label><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>S.H.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>S.X.</given-names></name></person-group><article-title>Roles of glucose transporter-1 and the phosphatidylinositol 3-kinase/protein kinase B pathway in cancer radioresistance (review)</article-title><source>Mol. Med. Rep.</source><volume>11</volume><year>2015</year><fpage>1573</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">25376370</pub-id></element-citation></ref><ref id="bib0095"><label>95</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>De Schutter</surname><given-names>H.</given-names></name><name><surname>Landuyt</surname><given-names>W.</given-names></name><name><surname>Verbeken</surname><given-names>E.</given-names></name><name><surname>Goethals</surname><given-names>L.</given-names></name><name><surname>Hermans</surname><given-names>R.</given-names></name><name><surname>Nuyts</surname><given-names>S.</given-names></name></person-group><article-title>The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy</article-title><source>BMC Cancer</source><volume>5</volume><year>2005</year><fpage>42</fpage><pub-id pub-id-type="pmid">15847702</pub-id></element-citation></ref><ref id="bib0096"><label>96</label><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name><surname>Kunkel</surname><given-names>M.</given-names></name><name><surname>Moergel</surname><given-names>M.</given-names></name><name><surname>Stockinger</surname><given-names>M.</given-names></name><name><surname>Jeong</surname><given-names>J.H.</given-names></name><name><surname>Fritz</surname><given-names>G.</given-names></name><name><surname>Lehr</surname><given-names>H.A.</given-names></name><name><surname>Whiteside</surname><given-names>T.L.</given-names></name></person-group><article-title>Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity</article-title><source>Oral Oncol.</source><volume>43</volume><year>2007</year><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">17207657</pub-id></element-citation></ref><ref id="bib0097"><label>97</label><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name><surname>Blatt</surname><given-names>S.</given-names></name><name><surname>Voelxen</surname><given-names>N.</given-names></name><name><surname>Sagheb</surname><given-names>K.</given-names></name><name><surname>Pabst</surname><given-names>A.M.</given-names></name><name><surname>Walenta</surname><given-names>S.</given-names></name><name><surname>Schroeder</surname><given-names>T.</given-names></name><name><surname>Mueller-Klieser</surname><given-names>W.</given-names></name><name><surname>Ziebart</surname><given-names>T.</given-names></name></person-group><article-title>Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years</article-title><source>Clin. Oral Investig.</source><volume>20</volume><year>2016</year><fpage>2097</fpage><lpage>2104</lpage></element-citation></ref><ref id="bib0098"><label>98</label><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name><surname>Sandulache</surname><given-names>V.C.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Skinner</surname><given-names>H.D.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Court</surname><given-names>L.E.</given-names></name><name><surname>Myers</surname><given-names>J.N.</given-names></name><name><surname>Meyn</surname><given-names>R.E.</given-names></name><name><surname>Fuller</surname><given-names>C.D.</given-names></name><name><surname>Bankson</surname><given-names>J.A.</given-names></name><name><surname>Lai</surname><given-names>S.Y.</given-names></name></person-group><article-title>Acute tumor lactate perturbations as a biomarker of genotoxic stress: development of a biochemical model</article-title><source>Mol. Cancer Ther.</source><volume>14</volume><year>2015</year><fpage>2901</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">26376962</pub-id></element-citation></ref><ref id="bib0099"><label>99</label><element-citation publication-type="journal" id="sbref0099"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>P.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Ni</surname><given-names>J.</given-names></name><name><surname>Wasinger</surname><given-names>V.</given-names></name><name><surname>Beretov</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Bucci</surname><given-names>J.</given-names></name><name><surname>Malouf</surname><given-names>D.</given-names></name><name><surname>Gillatt</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy</article-title><source>Oncotarget</source><volume>7</volume><year>2016</year><fpage>74269</fpage><lpage>74285</lpage><pub-id pub-id-type="pmid">27708237</pub-id></element-citation></ref><ref id="bib0100"><label>100</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Ridnour</surname><given-names>L.A.</given-names></name><name><surname>Thomas</surname><given-names>D.D.</given-names></name><name><surname>Switzer</surname><given-names>C.</given-names></name><name><surname>Flores-Santana</surname><given-names>W.</given-names></name><name><surname>Isenberg</surname><given-names>J.S.</given-names></name><name><surname>Ambs</surname><given-names>S.</given-names></name><name><surname>Roberts</surname><given-names>D.D.</given-names></name><name><surname>Wink</surname><given-names>D.A.</given-names></name></person-group><article-title>Molecular mechanisms for discrete nitric oxide levels in cancer</article-title><source>Nitric Oxide</source><volume>19</volume><year>2008</year><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">18472020</pub-id></element-citation></ref><ref id="bib0101"><label>101</label><element-citation publication-type="journal" id="sbref0101"><person-group person-group-type="author"><name><surname>Glynn</surname><given-names>S.A.</given-names></name><name><surname>Boersma</surname><given-names>B.J.</given-names></name><name><surname>Dorsey</surname><given-names>T.H.</given-names></name><name><surname>Yi</surname><given-names>M.</given-names></name><name><surname>Yfantis</surname><given-names>H.G.</given-names></name><name><surname>Ridnour</surname><given-names>L.A.</given-names></name><name><surname>Martin</surname><given-names>D.N.</given-names></name><name><surname>Switzer</surname><given-names>C.H.</given-names></name><name><surname>Hudson</surname><given-names>R.S.</given-names></name><name><surname>Wink</surname><given-names>D.A.</given-names></name><name><surname>Lee</surname><given-names>D.H.</given-names></name><name><surname>Stephens</surname><given-names>R.M.</given-names></name><name><surname>Ambs</surname><given-names>S.</given-names></name></person-group><article-title>Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients</article-title><source>J. Clin. Invest.</source><volume>120</volume><year>2010</year><fpage>3843</fpage><lpage>3854</lpage><pub-id pub-id-type="pmid">20978357</pub-id></element-citation></ref><ref id="bib0102"><label>102</label><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>H.</given-names></name><name><surname>Hayashi</surname><given-names>S.</given-names></name><name><surname>Hatashita</surname><given-names>M.</given-names></name><name><surname>Ohnishi</surname><given-names>K.</given-names></name><name><surname>Shioura</surname><given-names>H.</given-names></name><name><surname>Ohtsubo</surname><given-names>T.</given-names></name><name><surname>Kitai</surname><given-names>R.</given-names></name><name><surname>Ohnishi</surname><given-names>T.</given-names></name><name><surname>Kano</surname><given-names>E.</given-names></name></person-group><article-title>Induction of radioresistance by a nitric oxide-mediated bystander effect</article-title><source>Radiat. Res.</source><volume>155</volume><year>2001</year><fpage>387</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">11182788</pub-id></element-citation></ref><ref id="bib0103"><label>103</label><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name><surname>Cardnell</surname><given-names>R.J.</given-names></name><name><surname>Mikkelsen</surname><given-names>R.B.</given-names></name></person-group><article-title>Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts</article-title><source>PLoS ONE</source><volume>6</volume><year>2011</year><fpage>e20147</fpage><pub-id pub-id-type="pmid">21647438</pub-id></element-citation></ref><ref id="bib0104"><label>104</label><element-citation publication-type="journal" id="sbref0104"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>M.C.</given-names></name><name><surname>van der Donk</surname><given-names>W.A.</given-names></name></person-group><article-title>The many roles of glutamate in metabolism</article-title><source>J. Ind. Microbiol. Biotechnol.</source><volume>43</volume><year>2016</year><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">26323613</pub-id></element-citation></ref><ref id="bib0105"><label>105</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name></person-group><article-title>Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation</article-title><source>Biochim. Biophys. Acta</source><volume>1833</volume><year>2013</year><fpage>2996</fpage><lpage>3005</lpage><pub-id pub-id-type="pmid">23954443</pub-id></element-citation></ref><ref id="bib0106"><label>106</label><element-citation publication-type="journal" id="sbref0106"><person-group person-group-type="author"><name><surname>Son</surname><given-names>J.</given-names></name><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Ying</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hua</surname><given-names>S.</given-names></name><name><surname>Ligorio</surname><given-names>M.</given-names></name><name><surname>Perera</surname><given-names>R.M.</given-names></name><name><surname>Ferrone</surname><given-names>C.R.</given-names></name><name><surname>Mullarky</surname><given-names>E.</given-names></name><name><surname>Shyh-Chang</surname><given-names>N.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Fleming</surname><given-names>J.B.</given-names></name><name><surname>Bardeesy</surname><given-names>N.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Haigis</surname><given-names>M.C.</given-names></name><name><surname>DePinho</surname><given-names>R.A.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name><name><surname>Kimmelman</surname><given-names>A.C.</given-names></name></person-group><article-title>Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway</article-title><source>Nature</source><volume>496</volume><year>2013</year><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">23535601</pub-id></element-citation></ref><ref id="bib0107"><label>107</label><element-citation publication-type="journal" id="sbref0107"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>31151</fpage><lpage>31163</lpage><pub-id pub-id-type="pmid">26439804</pub-id></element-citation></ref><ref id="bib0108"><label>108</label><element-citation publication-type="journal" id="sbref0108"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group><article-title>Fundamentals of cancer metabolism</article-title><source>Sci. Adv.</source><volume>2</volume><year>2016</year><object-id pub-id-type="publisher-id">e1600200</object-id></element-citation></ref><ref id="bib0109"><label>109</label><element-citation publication-type="journal" id="sbref0109"><person-group person-group-type="author"><name><surname>Porporato</surname><given-names>P.E.</given-names></name><name><surname>Filigheddu</surname><given-names>N.</given-names></name><name><surname>Pedro</surname><given-names>J.M.B.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name><name><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Mitochondrial metabolism and cancer</article-title><source>Cell Res.</source><volume>28</volume><year>2018</year><fpage>265</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">29219147</pub-id></element-citation></ref><ref id="bib0110"><label>110</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>LeBleu</surname><given-names>V.S.</given-names></name><name><surname>O'Connell</surname><given-names>J.T.</given-names></name><name><surname>Gonzalez Herrera</surname><given-names>K.N.</given-names></name><name><surname>Wikman</surname><given-names>H.</given-names></name><name><surname>Pantel</surname><given-names>K.</given-names></name><name><surname>Haigis</surname><given-names>M.C.</given-names></name><name><surname>de Carvalho</surname><given-names>F.M.</given-names></name><name><surname>Damascena</surname><given-names>A.</given-names></name><name><surname>Domingos Chinen</surname><given-names>L.T.</given-names></name><name><surname>Rocha</surname><given-names>R.M.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Kalluri</surname><given-names>R.</given-names></name></person-group><article-title>PGC-1&#x003b1; mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis</article-title><source>Nat. Cell Biol.</source><volume>16</volume><year>2014</year><fpage>992</fpage><lpage>1003</lpage><comment>1001-1015</comment><pub-id pub-id-type="pmid">25241037</pub-id></element-citation></ref><ref id="bib0111"><label>111</label><element-citation publication-type="journal" id="sbref0111"><person-group person-group-type="author"><name><surname>Sancho</surname><given-names>P.</given-names></name><name><surname>Burgos-Ramos</surname><given-names>E.</given-names></name><name><surname>Tavera</surname><given-names>A.</given-names></name><name><surname>Bou Kheir</surname><given-names>T.</given-names></name><name><surname>Jagust</surname><given-names>P.</given-names></name><name><surname>Schoenhals</surname><given-names>M.</given-names></name><name><surname>Barneda</surname><given-names>D.</given-names></name><name><surname>Sellers</surname><given-names>K.</given-names></name><name><surname>Campos-Olivas</surname><given-names>R.</given-names></name><name><surname>GraAaAaAeA&#x0223c;a</surname><given-names>O.</given-names></name><name><surname>Viera</surname><given-names>C.R.</given-names></name><name><surname>Yuneva</surname><given-names>M.</given-names></name><name><surname>Sainz</surname><given-names>B.</given-names><suffix>Jr.</suffix></name><name><surname>Heeschen</surname><given-names>C.</given-names></name></person-group><article-title>MYC/PGC-1[alpha] balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells</article-title><source>Cell Metab.</source><volume>22</volume><year>2015</year><fpage>590</fpage><pub-id pub-id-type="pmid">26365176</pub-id></element-citation></ref><ref id="bib0112"><label>112</label><element-citation publication-type="journal" id="sbref0112"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Pettazzoni</surname><given-names>P.</given-names></name><name><surname>Lyssiotis</surname><given-names>C.A.</given-names></name><name><surname>Ying</surname><given-names>H.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>N.</given-names></name><name><surname>Marchesini</surname><given-names>M.</given-names></name><name><surname>Carugo</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>T.</given-names></name><name><surname>Seth</surname><given-names>S.</given-names></name><name><surname>Giuliani</surname><given-names>V.</given-names></name><name><surname>Kost-Alimova</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>F.</given-names></name><name><surname>Colla</surname><given-names>S.</given-names></name><name><surname>Nezi</surname><given-names>L.</given-names></name><name><surname>Genovese</surname><given-names>G.</given-names></name><name><surname>Deem</surname><given-names>A.K.</given-names></name><name><surname>Kapoor</surname><given-names>A.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Brunetto</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Wang</surname><given-names>Y.A.</given-names></name><name><surname>Heffernan</surname><given-names>T.P.</given-names></name><name><surname>Kimmelman</surname><given-names>A.C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Fleming</surname><given-names>J.B.</given-names></name><name><surname>Cantley</surname><given-names>L.C.</given-names></name><name><surname>DePinho</surname><given-names>R.A.</given-names></name><name><surname>Draetta</surname><given-names>G.F.</given-names></name></person-group><article-title>Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</article-title><source>Nature</source><volume>514</volume><year>2014</year><fpage>628</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">25119024</pub-id></element-citation></ref><ref id="bib0113"><label>113</label><element-citation publication-type="journal" id="sbref0113"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>D.</given-names></name><name><surname>Medeiros</surname><given-names>H.C.D.</given-names></name><name><surname>Zampieri</surname><given-names>L.X.</given-names></name><name><surname>Bol</surname><given-names>V.</given-names></name><name><surname>Danhier</surname><given-names>P.</given-names></name><name><surname>van Gisbergen</surname><given-names>M.W.</given-names></name><name><surname>Bouzin</surname><given-names>C.</given-names></name><name><surname>Brusa</surname><given-names>D.</given-names></name><name><surname>Gregoire</surname><given-names>V.</given-names></name><name><surname>Smeets</surname><given-names>H.</given-names></name><name><surname>Stassen</surname><given-names>A.P.M.</given-names></name><name><surname>Dubois</surname><given-names>L.J.</given-names></name><name><surname>Lambin</surname><given-names>P.</given-names></name><name><surname>Dutreix</surname><given-names>M.</given-names></name><name><surname>Sonveaux</surname><given-names>P.</given-names></name></person-group><article-title>Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells</article-title><source>Front. Pharmacol.</source><volume>11</volume><year>2020</year><fpage>263</fpage><pub-id pub-id-type="pmid">32231567</pub-id></element-citation></ref><ref id="bib0114"><label>114</label><element-citation publication-type="journal" id="sbref0114"><person-group person-group-type="author"><name><surname>Bokil</surname><given-names>A.</given-names></name><name><surname>Sancho</surname><given-names>P.</given-names></name></person-group><article-title>Mitochondrial determinants of chemoresistance</article-title><source>Cancer Drug Resist.</source><year>2019</year></element-citation></ref><ref id="bib0115"><label>115</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Jornayvaz</surname><given-names>F.R.</given-names></name><name><surname>Shulman</surname><given-names>G.I.</given-names></name></person-group><article-title>Regulation of mitochondrial biogenesis</article-title><source>Essays Biochem.</source><volume>47</volume><year>2010</year><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">20533901</pub-id></element-citation></ref><ref id="bib0116"><label>116</label><element-citation publication-type="journal" id="sbref0116"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Shao</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name></person-group><article-title>Nrf2 is a potential therapeutic target in radioresistance in human cancer</article-title><source>Crit. Rev. Oncol. Hematol.</source><volume>88</volume><year>2013</year><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">24126138</pub-id></element-citation></ref><ref id="bib0117"><label>117</label><element-citation publication-type="journal" id="sbref0117"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Pi</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Bode</surname><given-names>A.M.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>miR-504 mediated down-regulation of nuclear respiratory factor 1 leads to radio-resistance in nasopharyngeal carcinoma</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>15995</fpage><lpage>16018</lpage><pub-id pub-id-type="pmid">26201446</pub-id></element-citation></ref><ref id="bib0118"><label>118</label><element-citation publication-type="journal" id="sbref0118"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Misra</surname><given-names>V.</given-names></name><name><surname>Thimmulappa</surname><given-names>R.K.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Ames</surname><given-names>S.</given-names></name><name><surname>Hoque</surname><given-names>M.O.</given-names></name><name><surname>Herman</surname><given-names>J.G.</given-names></name><name><surname>Baylin</surname><given-names>S.B.</given-names></name><name><surname>Sidransky</surname><given-names>D.</given-names></name><name><surname>Gabrielson</surname><given-names>E.</given-names></name><name><surname>Brock</surname><given-names>M.V.</given-names></name><name><surname>Biswal</surname><given-names>S.</given-names></name></person-group><article-title>Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer</article-title><source>PLoS Med.</source><volume>3</volume><year>2006</year><fpage>e420</fpage><pub-id pub-id-type="pmid">17020408</pub-id></element-citation></ref><ref id="bib0119"><label>119</label><element-citation publication-type="journal" id="sbref0119"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Yegnasubramanian</surname><given-names>S.</given-names></name><name><surname>Esopi</surname><given-names>D.</given-names></name><name><surname>Kombairaju</surname><given-names>P.</given-names></name><name><surname>Bodas</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Bova</surname><given-names>S.G.</given-names></name><name><surname>Biswal</surname><given-names>S.</given-names></name></person-group><article-title>Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth</article-title><source>Mol. Cancer Ther.</source><volume>9</volume><year>2010</year><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">20124447</pub-id></element-citation></ref><ref id="bib0120"><label>120</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Nioi</surname><given-names>P.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name></person-group><article-title>A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>362</volume><year>2007</year><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">17822677</pub-id></element-citation></ref><ref id="bib0121"><label>121</label><element-citation publication-type="journal" id="sbref0121"><person-group person-group-type="author"><name><surname>Konstantinopoulos</surname><given-names>P.A.</given-names></name><name><surname>Spentzos</surname><given-names>D.</given-names></name><name><surname>Fountzilas</surname><given-names>E.</given-names></name><name><surname>Francoeur</surname><given-names>N.</given-names></name><name><surname>Sanisetty</surname><given-names>S.</given-names></name><name><surname>Grammatikos</surname><given-names>A.P.</given-names></name><name><surname>Hecht</surname><given-names>J.L.</given-names></name><name><surname>Cannistra</surname><given-names>S.A.</given-names></name></person-group><article-title>Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer</article-title><source>Cancer Res</source><volume>71</volume><year>2011</year><fpage>5081</fpage><lpage>5089</lpage><pub-id pub-id-type="pmid">21676886</pub-id></element-citation></ref><ref id="bib0122"><label>122</label><element-citation publication-type="journal" id="sbref0122"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.R.</given-names></name><name><surname>Oh</surname><given-names>J.E.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Kang</surname><given-names>M.R.</given-names></name><name><surname>Park</surname><given-names>S.W.</given-names></name><name><surname>Han</surname><given-names>J.Y.</given-names></name><name><surname>Eom</surname><given-names>H.S.</given-names></name><name><surname>Yoo</surname><given-names>N.J.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name></person-group><article-title>Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin</article-title><source>J. Pathol.</source><volume>220</volume><year>2010</year><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">19967722</pub-id></element-citation></ref><ref id="bib0123"><label>123</label><element-citation publication-type="journal" id="sbref0123"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>N.</given-names></name><name><surname>Izumi</surname><given-names>H.</given-names></name><name><surname>Miyamoto</surname><given-names>R.</given-names></name><name><surname>Kondo</surname><given-names>H.</given-names></name><name><surname>Tawara</surname><given-names>A.</given-names></name><name><surname>Sasaguri</surname><given-names>Y.</given-names></name><name><surname>Kohno</surname><given-names>K.</given-names></name></person-group><article-title>Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><volume>52</volume><year>2011</year><fpage>1055</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">21051700</pub-id></element-citation></ref><ref id="bib0124"><label>124</label><element-citation publication-type="journal" id="sbref0124"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>D.P.</given-names></name><name><surname>Scarpulla</surname><given-names>R.C.</given-names></name></person-group><article-title>Transcriptional regulatory circuits controlling mitochondrial biogenesis and function</article-title><source>Genes Dev.</source><volume>18</volume><year>2004</year><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">15004004</pub-id></element-citation></ref><ref id="bib0125"><label>125</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Luciakova</surname><given-names>K.</given-names></name><name><surname>Nelson</surname><given-names>B.D.</given-names></name></person-group><article-title>Expression of the human cytochrome c1 gene is controlled through multiple Sp1-binding sites and an initiator region</article-title><source>Eur. J. Biochem.</source><volume>241</volume><year>1996</year><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">8917468</pub-id></element-citation></ref><ref id="bib0126"><label>126</label><element-citation publication-type="journal" id="sbref0126"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.R.</given-names></name><name><surname>Chen</surname><given-names>X.J.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>L.F.</given-names></name><name><surname>Jiang</surname><given-names>H.P.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>L.J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>S.Q.</given-names></name></person-group><article-title>Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1</article-title><source>Cancer Manag. Res.</source><volume>11</volume><year>2019</year><fpage>5835</fpage><lpage>5844</lpage><pub-id pub-id-type="pmid">31303791</pub-id></element-citation></ref><ref id="bib0127"><label>127</label><element-citation publication-type="journal" id="sbref0127"><person-group person-group-type="author"><name><surname>Span</surname><given-names>P.N.</given-names></name><name><surname>Bussink</surname><given-names>J.</given-names></name></person-group><article-title>Biology of Hypoxia</article-title><source>Semin. Nucl. Med.</source><volume>45</volume><year>2015</year><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">25704383</pub-id></element-citation></ref><ref id="bib0128"><label>128</label><element-citation publication-type="journal" id="sbref0128"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>G.L.</given-names></name></person-group><article-title>Targeting HIF-1 for cancer therapy, Nature reviews</article-title><source>Cancer</source><volume>3</volume><year>2003</year><fpage>721</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">13130303</pub-id></element-citation></ref><ref id="bib0129"><label>129</label><element-citation publication-type="journal" id="sbref0129"><person-group person-group-type="author"><name><surname>Marampon</surname><given-names>F.</given-names></name><name><surname>Gravina</surname><given-names>G.L.</given-names></name><name><surname>Zani</surname><given-names>B.M.</given-names></name><name><surname>Popov</surname><given-names>V.M.</given-names></name><name><surname>Fratticci</surname><given-names>A.</given-names></name><name><surname>Cerasani</surname><given-names>M.</given-names></name><name><surname>Di Genova</surname><given-names>D.</given-names></name><name><surname>Mancini</surname><given-names>M.</given-names></name><name><surname>Ciccarelli</surname><given-names>C.</given-names></name><name><surname>Ficorella</surname><given-names>C.</given-names></name><name><surname>Di Cesare</surname><given-names>E.</given-names></name><name><surname>Festuccia</surname><given-names>C.</given-names></name></person-group><article-title>Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1&#x003b1; functional interplay</article-title><source>Int. J. Oncol.</source><volume>44</volume><year>2014</year><fpage>2121</fpage><lpage>2131</lpage><pub-id pub-id-type="pmid">24676782</pub-id></element-citation></ref><ref id="bib0130"><label>130</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>G.L.</given-names></name></person-group><article-title>Regulation of cancer cell metabolism by hypoxia-inducible factor 1</article-title><source>Semin. Cancer Biol.</source><volume>19</volume><year>2009</year><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">19114105</pub-id></element-citation></ref><ref id="bib0131"><label>131</label><element-citation publication-type="journal" id="sbref0131"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>T.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name></person-group><article-title>Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance</article-title><source>Exp. Cell Res.</source><volume>326</volume><year>2014</year><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">24930954</pub-id></element-citation></ref><ref id="bib0132"><label>132</label><element-citation publication-type="journal" id="sbref0132"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>S.</given-names></name><name><surname>Doyen</surname><given-names>J.</given-names></name><name><surname>Parks</surname><given-names>S.K.</given-names></name><name><surname>Bertero</surname><given-names>T.</given-names></name><name><surname>Paye</surname><given-names>A.</given-names></name><name><surname>Cardinaud</surname><given-names>B.</given-names></name><name><surname>Gounon</surname><given-names>P.</given-names></name><name><surname>Lacas-Gervais</surname><given-names>S.</given-names></name><name><surname>Noel</surname><given-names>A.</given-names></name><name><surname>Pouyssegur</surname><given-names>J.</given-names></name><name><surname>Barbry</surname><given-names>P.</given-names></name><name><surname>Mazure</surname><given-names>N.M.</given-names></name><name><surname>Mari</surname><given-names>B.</given-names></name></person-group><article-title>MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines</article-title><source>Cell Death Dis.</source><volume>4</volume><year>2013</year><fpage>e544</fpage><pub-id pub-id-type="pmid">23492775</pub-id></element-citation></ref><ref id="bib0133"><label>133</label><element-citation publication-type="journal" id="sbref0133"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Shan</surname><given-names>B.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance</article-title><source>J. Bone Oncol.</source><volume>5</volume><year>2016</year><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">27335774</pub-id></element-citation></ref><ref id="bib0134"><label>134</label><element-citation publication-type="journal" id="sbref0134"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y.M.</given-names></name><name><surname>Hu</surname><given-names>G.Y.</given-names></name><name><surname>Zhao</surname><given-names>X.Q.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>S.Y.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name></person-group><article-title>Hypoxia-induced autophagy contributes to radioresistance via c-Jun-mediated Beclin1 expression in lung cancer cells</article-title><source>J. Huazhong Univ. Sci. Technol. Med. Sci.</source><volume>34</volume><year>2014</year><fpage>761</fpage><lpage>767</lpage></element-citation></ref><ref id="bib0135"><label>135</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Q.I.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xin</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1&#x003b1;/miR-210/Bcl-2 pathway in colon cancer cells</article-title><source>Int. J. Oncol.</source><volume>46</volume><year>2015</year><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">25385144</pub-id></element-citation></ref><ref id="bib0136"><label>136</label><element-citation publication-type="journal" id="sbref0136"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>A.M.</given-names></name><name><surname>Lynam-Lennon</surname><given-names>N.</given-names></name><name><surname>O'Neill</surname><given-names>H.</given-names></name><name><surname>O'Sullivan</surname><given-names>J.</given-names></name></person-group><article-title>Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year></element-citation></ref><ref id="bib0137"><label>137</label><element-citation publication-type="journal" id="sbref0137"><person-group person-group-type="author"><name><surname>Storozhuk</surname><given-names>Y.</given-names></name><name><surname>Hopmans</surname><given-names>S.N.</given-names></name><name><surname>Sanli</surname><given-names>T.</given-names></name><name><surname>Barron</surname><given-names>C.</given-names></name><name><surname>Tsiani</surname><given-names>E.</given-names></name><name><surname>Cutz</surname><given-names>J.C.</given-names></name><name><surname>Pond</surname><given-names>G.</given-names></name><name><surname>Wright</surname><given-names>J.</given-names></name><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Tsakiridis</surname><given-names>T.</given-names></name></person-group><article-title>Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK</article-title><source>Br. J. Cancer</source><volume>108</volume><year>2013</year><fpage>2021</fpage><lpage>2032</lpage><pub-id pub-id-type="pmid">23632475</pub-id></element-citation></ref><ref id="bib0138"><label>138</label><element-citation publication-type="journal" id="sbref0138"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Ling</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>N.</given-names></name><name><surname>Fang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Lan</surname><given-names>W.</given-names></name><name><surname>Hou</surname><given-names>Z.</given-names></name><name><surname>Meng</surname><given-names>Q.</given-names></name><name><surname>Jin</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK</article-title><source>Biomed. Pharmacother.</source><volume>69</volume><year>2015</year><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">25661368</pub-id></element-citation></ref><ref id="bib0139"><label>139</label><element-citation publication-type="journal" id="sbref0139"><person-group person-group-type="author"><name><surname>Fasih</surname><given-names>A.</given-names></name><name><surname>Elbaz</surname><given-names>H.A.</given-names></name><name><surname>H&#x000fc;ttemann</surname><given-names>M.</given-names></name><name><surname>Konski</surname><given-names>A.A.</given-names></name><name><surname>Zielske</surname><given-names>S.P.</given-names></name></person-group><article-title>Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway</article-title><source>Radiat. Res.</source><volume>182</volume><year>2014</year><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">24909911</pub-id></element-citation></ref><ref id="bib0140"><label>140</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Ren</surname><given-names>S.</given-names></name><name><surname>Ji</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title><italic>Re</italic>-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway</article-title><source>Oncol Lett</source><volume>11</volume><year>2016</year><fpage>3197</fpage><lpage>3201</lpage><pub-id pub-id-type="pmid">27123089</pub-id></element-citation></ref><ref id="bib0141"><label>141</label><element-citation publication-type="journal" id="sbref0141"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>Y.K.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>E.H.</given-names></name><name><surname>Ha</surname><given-names>H.</given-names></name></person-group><article-title>Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins</article-title><source>PLoS ONE</source><volume>10</volume><year>2015</year><object-id pub-id-type="publisher-id">e0143596</object-id></element-citation></ref><ref id="bib0142"><label>142</label><element-citation publication-type="journal" id="sbref0142"><person-group person-group-type="author"><name><surname>Griss</surname><given-names>T.</given-names></name><name><surname>Vincent</surname><given-names>E.E.</given-names></name><name><surname>Egnatchik</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>E.H.</given-names></name><name><surname>Faubert</surname><given-names>B.</given-names></name><name><surname>Viollet</surname><given-names>B.</given-names></name><name><surname>DeBerardinis</surname><given-names>R.J.</given-names></name><name><surname>Jones</surname><given-names>R.G.</given-names></name></person-group><article-title>Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis</article-title><source>PLoS Biol.</source><volume>13</volume><year>2015</year><object-id pub-id-type="publisher-id">e1002309</object-id></element-citation></ref><ref id="bib0143"><label>143</label><element-citation publication-type="journal" id="sbref0143"><person-group person-group-type="author"><name><surname>Benej</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>X.</given-names></name><name><surname>Vibhute</surname><given-names>S.</given-names></name><name><surname>Scott</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Graves</surname><given-names>E.</given-names></name><name><surname>Le</surname><given-names>Q.T.</given-names></name><name><surname>Koong</surname><given-names>A.C.</given-names></name><name><surname>Giaccia</surname><given-names>A.J.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>C.S.</given-names></name><name><surname>Papandreou</surname><given-names>I.</given-names></name><name><surname>Denko</surname><given-names>N.C.</given-names></name></person-group><article-title>Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism</article-title><source>Proc. Natl. Acad. Sci. U S A</source><volume>115</volume><year>2018</year><fpage>10756</fpage><lpage>10761</lpage><pub-id pub-id-type="pmid">30201710</pub-id></element-citation></ref><ref id="bib0144"><label>144</label><element-citation publication-type="journal" id="sbref0144"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhuang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>2-Methoxyestradiol enhances radiosensitivity in radioresistant melanoma MDA-MB-435R cells by regulating glycolysis via HIF-1alpha/PDK1 axis</article-title><source>Int. J. Oncol.</source><volume>50</volume><year>2017</year><fpage>1531</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">28339028</pub-id></element-citation></ref><ref id="bib0145"><label>145</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Hau</surname><given-names>E.</given-names></name><name><surname>Joshi</surname><given-names>S.</given-names></name><name><surname>Dilda</surname><given-names>P.J.</given-names></name><name><surname>McDonald</surname><given-names>K.L.</given-names></name></person-group><article-title>Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism</article-title><source>Mol. Cancer Ther.</source><volume>14</volume><year>2015</year><fpage>1794</fpage><lpage>1804</lpage><pub-id pub-id-type="pmid">26063767</pub-id></element-citation></ref><ref id="bib0146"><label>146</label><element-citation publication-type="journal" id="sbref0146"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>A.M.</given-names></name><name><surname>Dunne</surname><given-names>M.R.</given-names></name><name><surname>Lynam-Lennon</surname><given-names>N.</given-names></name><name><surname>Kennedy</surname><given-names>S.A.</given-names></name><name><surname>Cannon</surname><given-names>A.</given-names></name><name><surname>Reynolds</surname><given-names>A.L.</given-names></name><name><surname>Maher</surname><given-names>S.G.</given-names></name><name><surname>Reynolds</surname><given-names>J.V.</given-names></name><name><surname>Kennedy</surname><given-names>B.N.</given-names></name><name><surname>O'Sullivan</surname><given-names>J.</given-names></name></person-group><article-title>Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma</article-title><source>Cancer Lett.</source><volume>447</volume><year>2019</year><fpage>115</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">30664962</pub-id></element-citation></ref><ref id="bib0147"><label>147</label><element-citation publication-type="journal" id="sbref0147"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>K.</given-names></name><name><surname>Sakakura</surname><given-names>C.</given-names></name><name><surname>Miyagawa</surname><given-names>K.</given-names></name><name><surname>Kuriu</surname><given-names>Y.</given-names></name><name><surname>Kin</surname><given-names>S.</given-names></name><name><surname>Nakase</surname><given-names>Y.</given-names></name><name><surname>Hagiwara</surname><given-names>A.</given-names></name><name><surname>Mitsufuji</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>Y.</given-names></name><name><surname>Hayashizaki</surname><given-names>Y.</given-names></name><name><surname>Yamagishi</surname><given-names>H.</given-names></name></person-group><article-title>Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation</article-title><source>Br. J. Cancer</source><volume>91</volume><year>2004</year><fpage>1543</fpage><lpage>1550</lpage><pub-id pub-id-type="pmid">15365572</pub-id></element-citation></ref><ref id="bib0148"><label>148</label><element-citation publication-type="journal" id="sbref0148"><person-group person-group-type="author"><name><surname>Candas</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>C.L.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name><name><surname>Chuang</surname><given-names>F.Y.</given-names></name><name><surname>Sweeney</surname><given-names>C.</given-names></name><name><surname>Borowsky</surname><given-names>A.D.</given-names></name><name><surname>Li</surname><given-names>J.J.</given-names></name></person-group><article-title>Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells</article-title><source>Cancer Res.</source><volume>74</volume><year>2014</year><fpage>7498</fpage><lpage>7509</lpage><pub-id pub-id-type="pmid">25377473</pub-id></element-citation></ref></ref-list></back></article>